Scorpius (SCPX) 10-K 27 Mar 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 27, 2015	Jun. 30, 2014
Document and Entity Information [Abstract]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Entity Registrant Name	HEAT BIOLOGICS, INC.
Entity Central Index Key	1476963
Current Fiscal Year End Date	-19
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		8,394,456
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$24,626,449

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current Assets
Cash and cash equivalents	$3,714,304	$4,566,992
Investments, held to maturity (net)	10,698,982	17,297,165
Prepaid expenses and other current assets	863,227	1,066,638
Total Current Assets	15,276,513	22,930,795
Property and Equipment, net	445,534	53,753
Other Assets
Restricted cash	101,129	1,252
Deposits	19,798	9,320
Related party receivable	48,642	24,946
Deferred financing costs, net	24,554
Total Other Assets	194,123	35,518
Total Assets	15,916,170	23,020,066
Current Liabilities
Accounts payable	1,367,426	651,917
Accrued expenses and other payables	805,968	503,050
Accrued interest		25,364
Current portion of long term debt	397,465
Total Current Liabilities	2,570,859	1,180,331
Long Term Liabilities
Long term debt, net of discount and current portion	2,314,124
Stock warrants liability		122,590
Total Liabilities	4,884,983	1,302,921
Commitments and Contingencies - see Note 15
Stockholders' Equity
Common stock, $.0002 par value; 50,000,000 shares authorized, 6,492,622 and 6,375,426 issued and outstanding at December 31, 2014 and 2013, respectively	982	961
Additional paid in capital	35,894,823	34,337,591
Accumulated deficit	-24,135,447	-12,346,630
Total Stockholders' Equity - Less Non-Controlling Interest	11,760,358	21,991,922
Non-Controlling Interest	-729,171	-274,777
Total Stockholders' Equity	11,031,187	21,717,145
Total Liabilities and Stockholders' Equity	$15,916,170	$23,020,066

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Common stock, par value per share	$0.00	$0.00
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	6,492,622	6,375,426
Common stock, shares outstanding	6,492,622	6,375,426

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Operating expenses:
Research and development	$2,861,231	$2,737,688
Clinical and regulatory	5,348,091	1,397,157
General and administrative	3,977,605	2,429,796
Total operating expenses	12,186,927	6,564,641
Loss from operations	-12,186,927	-6,564,641
Interest income	40,570	10,068
Other (expense) income	-23,500	23,828
Interest expense	-73,354	-79,119
Total non-operating income (expense)	-56,284	-45,223
Net loss	-12,243,211	-6,609,864
Net loss - non-controlling interest	-454,394	-198,516
Beneficial conversion charge		-2,300,000
Preferred stock dividend		-361,668
Net loss attributable to common stockholders	($11,788,817)	($9,073,016)
Net loss per share attributable to common stockholders-basic and diluted	($1.83)	($2.42)
Weighted number of common shares used in net loss attributable to common stockholders - basic and diluted	6,454,866	3,747,357

Consolidated_Statement_of_Stoc

Consolidated Statement of Stockholders Equity (USD $)	Total	Series 1 Preferred Stock [Member]	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]	Common Stock [Member]	APIC [Member]	Accumulated Deficit [Member]	Non-Controlling Interest [Member]
Balance at Dec. 31, 2012	($1,515,109)	$11	$186		$405	$4,495,832	($5,935,282)	($76,261)
Preferred Stock Issued	5,050,090			189		5,049,901
Common Stock Issued: Preferred Series 1 Converted to Common Stock		-11				11
Common Stock Issued: Preferred Series A Converted to Common Stock			-186			186
Common Stock Issued: Preferred Series B Converted to Common Stock				-189		189
Common Stock Issued	25,110,540				540	25,110,000
Exercise of stock options	54,042				16	54,026
Common Stock Issued: Vesting of restricted stock
Common Stock Issued: Preferred Stock Dividend
Stock based compensation	571,924					571,924
Stock issuance costs	-944,478					-944,478
Net loss	-6,609,864						-6,411,348	-198,516
Balance at Dec. 31, 2013	21,717,145				961	34,337,591	-12,346,630	-274,777
Exercise of stock options	37,936				13	37,923
Cashless exercise of options
Cashless exercise of warrants	452,874				8	452,866
Stock based compensation	1,066,443					1,066,443
Net loss	-12,243,211						-11,788,817	-454,394
Balance at Dec. 31, 2014	$11,031,187				$982	$35,894,823	($24,135,447)	($729,171)

Consolidated_Statement_of_Stoc1

Consolidated Statement of Stockholders Equity (Parenthetical) (USD $)	1 Months Ended	12 Months Ended		1 Months Ended
	Jul. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2013	Mar. 25, 2013
Equity Issuance [Line Items]
Common Stock Issued, shares	2,500,000
Common Stock [Member]
Equity Issuance [Line Items]
Common Stock Issued, shares			2,700,000
Exercise of stock options, shares		66,707	80,706
Common Stock Issued: Vesting of restricted stock, shares			2,899
Cashless exercise of options, shares		10,442
Cashless exercise of warrants, shares		40,047
Preferred Stock [Member]
Equity Issuance [Line Items]
Common Stock Issued: Preferred Series 1 Converted to Common Stock, shares	49,960
Common Stock Issued: Preferred Series A Converted to Common Stock, shares	810,057
Common Stock Issued: Preferred Series B Converted to Common Stock, shares	836,666
Common Stock Issued: Preferred Stock Dividend, shares	36,167
Series B Preferred Stock [Member]
Equity Issuance [Line Items]
Preferred Stock Issued, shares				1,891,419
Share Price					$2.67

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash Flows from Operating Activities
Net loss	($12,243,211)	($6,609,864)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	66,895	6,348
Amortization of debt issuance costs	37,556	28,229
Amortization of bond premium	173,204	50,781
Re-measurement of fair value of stock warrant liability	7,263	30,440
Stock based compensation	1,066,443	571,924
Increase (decrease) in cash arising from changes in assets and liabilities:
Related party receivable	-23,696	-15,375
Prepaid expenses and other current assets	203,411	-1,008,202
Restricted cash	-99,877	24,962
Deposits	-10,478
Accounts payable	715,509	146,446
Accrued expenses and other payables	302,918	373,842
Accrued interest	-25,364	11,601
Net Cash Used by Operating Activities	-9,829,427	-6,388,868
Cash Flows from Investing Activities
Proceeds from maturities of short-term investments	18,623,826
Purchases of short term investments	-12,198,847	-17,347,946
Purchase of property and equipment	-458,676	-49,319
Net Cash Provided by (Used in) Investing Activities	5,966,303	-17,397,265
Cash Flows from Financing Activities
Proceeds from initial public offering, net of underwriting discounts		25,110,000
Proceeds from long term debt, net	2,972,500
Borrowings on notes payable		200,000
Payments on notes payable		-925,000
Issuance of convertible notes payable, net of issuance costs		-197,099
Issuance of common stock		540
Proceeds from the exercise of stock options	37,936	54,042
Stock issuance costs		-944,478
Net Cash Provided by Financing Activities	3,010,436	28,348,095
Net (Decrease) Increase in Cash and Cash Equivalents	-852,688	4,561,962
Cash and Cash Equivalents - Beginning of Period	4,566,992	5,030
Cash and Cash Equivalents - End of Period	3,714,304	4,566,992
Supplemental Disclosure for Cash Flow Information
Interest paid	32,025	60,922
Supplemental Schedule of Noncash Investing and Financing Activities
Beneficial conversion charge		2,300,000
Non-cash conversion of preferred stock into common stock		386
Preferred conversion of preferred stock into common stock		361,668
Cashless exercise of stock warrants	452,874
Issuance of warrants	323,021
Series B-1 Preferred Stock [Member]
Cash Flows from Financing Activities
Issuance of preferred stock		$5,050,090

Organization

Organization	12 Months Ended
	Dec. 31, 2014
Organization [Abstract]
Organization	1
	Organization
	Heat Biologics, Inc. (“Heat” or “the Company”), was incorporated in 2008 pursuant to the laws of the state of Delaware. Heat Biologics, Inc. is a development stage company focused on the development and commercialization of ImPact™ Therapy, a platform technology that offers a novel approach to treating cancer and other diseases by using live, modified cell lines to activate the immune system against specific defined targets. Heat is currently in Phase II clinical trials with its first drug for patients with advanced non-small cell lung cancer.  During 2010 and part of 2011, Heat was headquartered in Miami Beach, Florida. In July 2011, Heat moved its headquarters to Chapel Hill, North Carolina. In May 2014, Heat moved its headquarters and established a lab facility in Durham, North Carolina.
	Heat owns 92.5% interest in its subsidiary, Heat Biologics I, Inc. On May 30, 2012, Heat formed two-wholly owned subsidiaries, Heat Biologics III, Inc. (“Heat III”) and Heat Biologics, IV, Inc. (“Heat IV”). Heat formed Heat Biologics GmbH (Heat GmbH), a wholly-owned limited liability company, organized in Germany on September 11, 2012. Heat also formed Heat Biologics Australia Pty LTD, a wholly-owned proprietary company, registered in Australia on March 14, 2014.
	Heat's product candidates require clinical trials and approvals from regulatory agencies, as well as acceptance in the marketplace. Part of Heat's strategy is to develop and commercialize some of its product candidates by continuing existing arrangements with academic and corporate collaborators and licensees and by entering into new collaborations.

Summary_of_Significant_Account

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2014

Summary of Significant Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2

Summary of Significant Accounting Policies

Basis of Accounting

The accompanying consolidated financial statements have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Principles of Consolidation

The consolidated financial statements include the accounts of Heat Biologics, Inc. and its subsidiaries, Heat Biologics I, Inc. (“Heat I”) Heat Biologics III, Inc. (“Heat III”), Heat Biologics IV, Inc. (“Heat IV”), Heat Biologics GmbH and Heat Biologics Australia Pty Ltd. All significant intercompany accounts and transactions have been eliminated in consolidation. At December 31, 2014 and 2013, Heat held a 92.5% controlling interest in Heat I and accounts for its less than 100% interest in the consolidated financial statements in accordance with U.S. GAAP. Accordingly, the Company presents non-controlling interests as a component of stockholders' equity  on its consolidated balance sheets and reports non-controlling interest net loss under the heading “net loss – non-controlling interest” in the consolidated statements of operations.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Estimates are used for, but not limited to, useful lives of fixed assets, income taxes and stock-based compensation. Actual results may differ from those estimates.

Cash and Cash Equivalents and Restricted Cash

The Company considers all cash and other highly liquid investments with initial maturities from the date of purchase of three months or less to be cash and cash equivalents. The Company had a restricted cash balance of $101,129 and $1,252 at December 31, 2014 and 2013, respectively. The United States Patent and Trade Office (“USPTO”) requires the Company to maintain an account with a minimum of $1,000 to be used to pay fees associated with new trademarks of the Company and one of the Company's lenders required a minimum $100,000 cash balance to be maintained with the lending bank to secure the Company credit card during 2014.

Concentration of Credit Risk

At times, cash balances may exceed the Federal Deposit Insurance Corporation (“FDIC”) insurable limits. The Company has never experienced any losses related to these balances. As of December 31, 2014 and 2013, cash amounts in excess of $250,000 were not fully insured. The uninsured cash balance as of December 31, 2014 was $3,704,026. The Company does not believe it is exposed to significant credit risk on cash and cash equivalents.

Deferred Financing Costs, net

Deferred financing costs, net include the costs incurred to obtain financing and are amortized using the straight-line method, which approximates the effective interest method, over the life of the related debt. Deferred financing costs, net are included in the accompanying consolidated balance sheets net of amortization.

Property and Equipment

Property and equipment are stated at cost and are capitalized if the cost exceeds $500. Depreciation is calculated using the straight-line method and is based on estimated useful lives of five years for lab equipment and computer equipment, and seven years for furniture and fixtures.

Stock Warrants Liability

In 2012 and 2013, the Company issued warrants exercisable for a total of 20,549 shares of common stock. The freestanding warrants for the Company's common stock were recognized as a liability and recorded at fair value in all periods prior to exercise. Upon the cashless exercise of these warrants in January and February 2014, the sum of the fair value of the exercised warrants were credited to additional paid in capital and the liability was eliminated.

In connection with the Square 1 Bank Loan (“Loan”), in August 2014, the Company issued Square 1 Bank a warrant, exercisable for 52,695 shares of the Company's common stock at an exercise price of $4.27. In accordance with ASC 480-10, Distinguishing Liabilities from Equity, the freestanding warrant for the Company's common stock was recognized as a liability and recorded at fair value in all periods prior to exercise. The warrant liability was re-measured to fair value prior to reclassification to additional paid in capital upon its exercise.  The initial fair value of the warrant of $323,021 was recorded as a liability and a discount to notes payable and is being amortized to interest expense over the term of the note. In September 2014, the warrants were exercised via a cashless exercise into 17,664 shares of the Company's common stock.

The fair value of the warrants was calculated using the Black-Scholes option pricing model with the following assumptions:

December 31,

2014

2013

Risk-free interest rate

2.23-2.46

%

2.75

%

Expected volatility

73.0-100

%

71.6-71.9

%

Expected life (years)

7.8-10

7.96-8.6

Expected dividend yield

0

%

0

%

The Company had no stock warrant liability as of December 31, 2014.

Beneficial Conversion Feature

When the Company issues an equity security that is convertible into common stock at a discount from the fair value of the common stock at the date the equity security counterparty is legally committed to purchase such a security (Commitment Date), a beneficial conversion charge is measured and recorded on the Commitment Date for the difference between the fair value of the Company's common stock and the effective conversion price of the equity security. If the intrinsic value of the beneficial conversion feature is greater than the proceeds allocated to the equity security, the amount of the discount assigned to the beneficial conversion feature is limited to the amount of the proceeds allocated to the equity.

The amount allocated to the beneficial conversion feature is presented as an immediate charge to earnings available to common stockholders for convertible preferred stock instruments that are convertible by the stockholders at any time. In connection with the Company's issuance of Series B-1 Preferred Stock during fiscal year 2013, the Company recorded a beneficial conversion charge of $2.3 million representing the difference between the effective conversion price of $6.14 and the fair value of the Company's common stock as of the Commitment Date of $8.81.

Net Loss per Share

Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during each year. Fully diluted net loss per share is computed using the weighted average number of common shares and dilutive securities outstanding during each year. Dilutive securities having an anti-dilutive effect on diluted loss per share are excluded from the calculation.

Fair Value of Financial Instruments

The carrying amount of certain of the Company's financial instruments, including cash and cash equivalents, prepaid expenses and other current assets, deposits, accounts payable and accrued expenses and other payables approximate fair value due to their short maturities. The carrying value of debt approximates fair value because the interest rate under the obligation approximates market rates of interest available to the Company for similar instruments.

As a basis for determining the fair value of certain of the Company's financial instruments, the Company utilizes a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

Level I – Observable inputs such as quoted prices in active markets for identical assets or liabilities.

Level II – Observable inputs, other than Level I prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level III – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The Company's financial instruments that are measured at fair value on a recurring basis consist only of the stock warrants liability. The Company's stock warrants liability was classified within Level III of the fair value hierarchy and as of December 31, 2014 and 2013.

The change in the fair value of the Level III warrants liability is summarized below:

Fair value at December 31, 2012

$

92,150

Change in fair value during the period

30,440

Fair value at December 31, 2013

122,590

Issuance of new warrants

323,021

Change in fair value during the period

7,263

Cashless exercise during the period

(452,874

)

Fair value at December 31, 2014

$

—

There were no assets or liabilities measured at fair value on a recurring basis as of December 31, 2014. The liabilities measured at fair value on a recurring basis as of December 31, 2013 are summarized below:

31-Dec-13

Identical

Observable

Unobservable

Total

Assets

Inputs

Inputs

December 31,

Description

(Level 1)

(Level 2)

(Level 3)

2013

Liabilities measured at fair value

Stock Warrant Liability

$

—

$

—

$

(122,590

)

$

(122,590

)

Total Liabilities measured at fair value

$

—

$

—

$

(122,590

)

$

(122,590

)

Marketing

Marketing costs are expensed as incurred. Marketing expense totaled $135,372 and $135,366 for the years ended December 31, 2014 and 2013, respectively.

Income Tax

Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying amounts of assets and liabilities and their respective tax bases, operating loss carryforwards, and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

In accordance with FASB ASC 740, Accounting for Income Taxes, the Company reflects in the financial statements the benefit of positions taken in a previously filed tax return or expected to be taken in a future tax return only when it is considered ‘more-likely-than-not' that the position taken will be sustained by a taxing authority. As of December 31, 2014 and 2013, the Company had no unrecognized income tax benefits and correspondingly there is no impact on the Company's effective income tax rate associated with these items. The Company's policy for recording interest and penalties relating to uncertain income tax positions is to record them as a component of income tax expense in the accompanying consolidated statements of operations. As of December 31, 2014 and 2013, the Company had no such accruals.

Stock-Based Compensation

The Company accounts for stock-based compensation arrangements with employees and non-employee directors using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments, including stock options. The fair value method requires the Company to estimate the fair value of stock-based payment awards on the date of grant using an option pricing model.

Stock-based compensation costs are based on the fair value of the underlying option calculated using the Black-Scholes-Merton option pricing model on the date of grant for stock options and recognized as expense on a straight-line basis over the requisite service period, which is the vesting period. Determining the appropriate fair value model and related assumptions requires judgment, including estimating stock price volatility, forfeiture rates and expected term. The expected volatility rates are estimated based on the actual volatility of comparable public companies over the expected term. The expected term for the years ended December 31, 2014 and 2013 represents the average time that options are expected to be outstanding based on the mid-point between the vesting date and the end of the contractual term of the award. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company has not paid dividends and does not anticipate paying a cash dividend in the foreseeable future and, accordingly, uses an expected dividend yield of zero. The risk-free interest rate is based on the rate of U.S. Treasury securities with maturities consistent with the estimated expected term of the awards. The measurement of nonemployee share-based compensation is subject to periodic adjustments as the underlying equity instruments vest and is recognized as an expense over the period over which services are received.

Net loss attributable to non-controlling interests

Net loss attributable to non-controlling interests is the result of the Company's consolidation of subsidiaries of which it does not own 100%. The Company's net loss attributable to non-controlling interests relates to the University's ownership in Heat I, for the years ended December 31, 2014 and 2013.

Revenue Recognition

The Company recognizes government grants when there is reasonable assurance that they will comply with the conditions attached to the grants and the grants will be received. The grants are recognized using an income approach and grant revenue is recognized as the related expenses are incurred.

Research and Development

Research and development costs are expensed as incurred. The Company has acquired exclusive licensing rights to intellectual property to further its research and development. These costs are expensed as incurred. The Company also incurs intellectual property costs relating to the filing and application fees for patents which are owned by the universities with which the Company has license agreements. These costs are also expensed as research and development expense as incurred.

Impact of recently issued Accounting Standards:

In July 2014, the FASB issued Accounting Standards Update (“ASU”) ASU No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. The amendments in this ASU remove all incremental financial reporting requirements from U.S. GAAP for development stage entities, including the removal of Topic 915, Development Stage Entities, from the FASB Accounting Standards Codification™. A development stage entity is one that devotes substantially all of its efforts to establishing a new business and for which: (a) planned principal operations have not commenced; or (b) planned principal operations have commenced, but have produced no significant revenue. Current U.S. GAAP requires a development stage entity to present the same basic financial statements and apply the same recognition and measurement rules as established companies. In addition, U.S. GAAP requires a development stage entity to present inception-to-date information about income statement line items, cash flows, and equity transactions. For public business entities, the presentation and disclosure requirements in Topic 915 will no longer be required for the first annual period beginning after December 15, 2014. The revised consolidation standards are effective one year later, in annual periods beginning after December 15, 2015. Early adoption is permitted for financial statements that have not yet been issued or made available for issuance. The Company has elected to adopt the guidance as of June 30, 2014. The adoption did not impact the Company's financial position or results of operations.

In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (“ASU 2014-15”). The amendments in ASU 2014-15 are intended to define management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. Under GAAP, financial statements are prepared under the presumption that the reporting organization will continue to operate as a going concern, except in limited circumstances. The going concern basis of accounting is critical to financial reporting because it establishes the fundamental basis for measuring and classifying assets and liabilities. Currently, GAAP lacks guidance about management's responsibility to evaluate whether there is substantial doubt about the organization's ability to continue as a going concern or to provide related footnote disclosures. This ASU provides guidance to an organization's management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations today in the financial statement footnotes. This update is effective for annual periods ending after December 15, 2016, and interim periods within annual periods beginning after December 15, 2016. Early application is permitted for annual or interim reporting periods for which the financial statements have not previously been issued. We do not expect this ASU to have an impact on its consolidated financial statements.

In January 2015, the FASB issued ASU No. 2015-1, Income Statement - Extraordinary and Unusual Items. ASU 2015-01 will eliminate from U.S. GAAP the concept of extraordinary items and will no longer require an entity to separately classify, present, and disclose extraordinary events and transactions. ASU 2015-01 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015, and early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption. The Company does not believe the adoption of this guidance will have a material impact on its consolidated financial statements or related footnote disclosures.

Investments

Investments	12 Months Ended
	Dec. 31, 2014
Investments [Abstract]
Investments	3.
	Investments
	Investments in certain securities may be classified into three categories:
	•
	Held-to-maturity - Debt securities that the Company has the positive intent and ability to hold to maturity are reported at amortized cost.
	•
	Trading securities - Debt and equity securities that are bought and held principally for the purpose of selling in the near term are reported at fair value with unrealized gains and losses included in earnings.
	•
	Available-for-sale - Debt and equity securities not classified as either securities held-to-maturity or trading securities are reported at fair value with unrealized gains or losses excluded from earnings and reported as a separate component of stockholders' equity.
	The Company reassesses the appropriateness of the classification of its investments at the end of each reporting period. The Company has determined that its debt securities should be classified as held-to-maturity as of December 31, 2014 and 2013. This classification was based upon management's determination that it has the positive intent and ability to hold the securities until their maturity dates, as the underlying cash invested in these securities is not required for current operations. Investments consist of short-term FDIC insured certificates of deposit, commercial paper rated A1/P1 or above and corporate notes and bonds rated A and above carried at amortized cost using the effective interest method.
	The following summarizes information about short term investments at December 31, 2014 and 2013, respectively:
		Amortized		Gross		Estimated
		Cost		Unrealized		Fair Value
				Losses
	2014
	Certificates of deposit, commercial paper	$	10,698,982	$	2,209	$	10,696,773
	2013
	Certificates of deposit, commercial paper	$	17,297,165	$	16,493	$	17,280,672
	As of December 31, 2014 and 2013, the estimated fair value of the investments was less than the amortized cost. Because management intends to hold the investments until their maturity dates, these unrealized losses were not recorded in the consolidated financial statements.
	The maturities of held-to-maturity investments at December 31, 2014 and 2013, respectively were as follows:
		Less than		Total
		1 Year
	2014
	Certificates of deposit, commercial paper	$	10,698,982	$	10,698,982
	2013
	Certificates of deposit, commercial paper	$	17,297,165	$	17,297,165

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2014
Property and Equipment [Abstract]
Property and Equipment	4
	Property and Equipment
	Property and equipment are recorded at cost and depreciated using the straight-line method, over estimated useful lives, ranging generally from five to seven years. Expenditures for maintenance and repairs are charged to expense as incurred.
	Property and equipment consisted of the following at:
		December 31,
		2014			2013
	Furniture and fixtures	$	50,391		$	10,780
	Computers		24,174			13,175
	Lab equipment		447,423			39,357
	Total		521,988			63,312
	Accumulated depreciation		(76,454	)		(9,559	)
	Property and equipment, net	$	445,534		$	53,753
	Depreciation expense totaled $66,895 and $6,348 for the years ended December 31, 2014 and 2013, respectively.

Accrued_Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2014
Accrued Expenses [Abstract]
Accrued Expenses	5
	Accrued Expenses
	Accrued expenses consist of the following at:
		December 31,
		2014		2013
	Compensation and related benefits	$	519,092	$	356,588
	Patent fees		40,000		40,000
	Deferred Rent		51,155		—
	Accrued clinical trial expense		195,721		106,462
		$	805,968	$	503,050

Debt_Issuance_Costs

Debt Issuance Costs	12 Months Ended
	Dec. 31, 2014
Debt Issuance Costs [Abstract]
Debt Issuance Costs	6
	Debt Issuance Costs
	During 2014 the Company recorded $323,021 to debt discount for the initial fair value of the warrant to purchase common stock and $27,500 to deferred financing costs related to third party fees paid in connection to the Square 1 Bank loan, which are amortized over the 42 months term of the loan.
	Total amortization expense for the debt issuance costs was $37,556 and $28,229 during fiscal year 2014 and 2013, respectively.

Convertible_Notes_Payable

Convertible Notes Payable	12 Months Ended
	Dec. 31, 2014
Convertible Notes Payable [Abstract]
Convertible Notes Payable	7
	Convertible Notes Payable
	On October 20, 2011, the Company entered into a convertible note agreement with a vendor for an amount up to $950,000. The note accrues 12% simple interest per annum beginning on the day of the first advance. The note is convertible into common or Series A preferred stock at the latest valuation. The type of security converted will depend on whether common or Series A preferred stock is issued as part of a successful future equity raise of at least $7.5 million at the qualified offering price. Unless earlier converted into equity, the note will be payable upon demand after the eighth anniversary of the execution date of the vendor agreement which occurs in October 2019. The agreement allows the vendor to treat unpaid invoices as advances of principal under the promissory note. The note payable balance of  $197,099 was paid off in July 2013 and terminated.

Notes_Payable

Notes Payable	12 Months Ended
	Dec. 31, 2014
Notes Payable [Abstract]
Notes Payable	8
	Notes Payable
	On August 7, 2012, the Company entered into a loan and security agreement (“the Loan and Security Agreement”) with a bank. The terms of the agreement provide for a $1,000,000 term loan (“Tranche A”) to be available to the Company as of the date of the Loan and Security Agreement. The Tranche A term loan may be increased to $2,775,000 upon the Company receiving grant funding totaling at least $16,000,000. The Tranche A term loan accrues interest monthly at an interest rate of 3% plus Prime or 6% per annum, whichever is greater. The Tranche A term loan principal balance, along with any accrued interest, is to be paid in thirty-six equal monthly installments beginning September 7, 2013 and ending August 7, 2016. Additionally, the Loan and Security Agreement provides for a term loan in an aggregate principal amount not to exceed $225,000 (“Term Loan B”). Payments of 5% of the outstanding principal balance, plus accrued interest are each due on August 2013 and 2014, with the remaining principal balance, plus all accrued interest, due December 14, 2014. The term loan accrues interest monthly at 4.25% per annum. On August 27, 2013, the Company repaid the entire outstanding balance on the Tranche A term loan and the Term Loan B with the bank, in the amount of $725,000 and the loan agreement was terminated.
	On January 10, 2013, the Company signed a Second Amendment to its Loan and Security Agreement which granted an extension of credit in the form of a Non-Formula Revolving Line (“the Non-Formula Line”) for an amount up to $200,000. This increase in credit was through a limited guaranty by an investor who secured the additional obligation by maintaining as collateral a money market account of a minimum of $200,000 with the bank. This guarantee was only for the amounts arising from the Non-Formula Line. It was the intention of both the investor and the Company that the Non-Formula Line was to be repaid within a reasonable time period after the successful raise of capital but no later than January 9, 2014, the maturity date of the Non-Formula Line. The payoff of the Non-Formula Line would release the investor of its obligation to the bank. The Company borrowed $200,000 on the Non-Formula Line in January 2013, and the entire balance was paid in April 2013.
	In conjunction with the Loan and Security Agreement, the Company issued warrants to the bank to purchase 17,500 shares of Heat's Series A Preferred Stock. The warrants were issued on August 7, 2012 with an initial exercise price of $4.83 per share and expire on August 7, 2022. The warrants converted from preferred stock warrants into 7,609 warrants to purchase common stock upon the completion of the initial public offering in July 2013 and the number of shares were adjusted for the 1-for-2.3 reverse stock split.  In February 2014, all 7,609 warrants were exercised in cashless transactions that resulted in the issuance of 3,072 shares of common stock.
	In August 2014, the Company entered into a secured loan with Square 1 Bank (“Loan”). The Loan provides the Company with a term loan in the aggregate principal amount not to exceed $7,500,000 to be used to supplement working capital.  The Loan is available to the Company in four tranches:  $1,500,000 was made available to the Company on August 22, 2014 (“Tranche 1 Loan”), $1,500,000 became available to the Company upon its enrollment of its first patient in its the Phase 2 clinical trial for HS-110 (“Tranche 2 Loan ”), $2,250,000 will be available to the Company upon Square 1 Bank's receipt or before June 30, 2015 of evidence satisfactory to it of the initiation and continuation of the ImPACT™ cell line for a third indication (“Tranche 3 Loan”) and $2,250,000 will be available to the Company upon Square 1 Bank's receipt or before October 31, 2015 of evidence satisfactory to it of the full enrollment of our Phase 1/2 clinical trial for HS -410 (“Tranche 4 Loan”). As of December 31, 2014, the Company had drawn down $1,500,000 each under the Tranche 1 Loan and Tranche 2 Loan, totaling $3,000,000.
	The Loan accrues interest monthly at an interest rate of 3.05% plus prime or 6.30 % per annum whichever is greater. The Tranche 1 Loan was payable as interest-only until December 31, 2014, upon which the Company drew down the Tranche 2 Loan, extending the interest-only until June 30, 2015. The Tranche 1 Loan is payable in monthly installments of principal plus accrued interest until February 22, 2018.   The Tranche 2 Loan is available prior to December 31, 2014 and is payable as interest-only prior to June 30, 2015 (unless the Company achieves the Tranche 3 milestone at which time the interest only period will be extended until October 31, 2015) and thereafter is payable in monthly installments of principal plus accrued interest until February 22, 2018. The Tranche 3 Loan is available until June 30, 2015 and is payable as interest-only prior to October 31, 2015 and thereafter is payable in monthly installments of principal plus accrued interest until February 22, 2018. The Tranche 4 Loan is available until October 31, 2015 and is payable in monthly installments of principal plus accrued interest until February 22, 2018.  As of December 31, 2014, the Company has made $0 in principal payments and $24,150 in interest payments on the outstanding loan. The agreement with Square 1 Bank sets forth various affirmative and negative covenants. The failure of the Company to comply with the covenants constitutes a default under the Loan. The covenants include the Company having at least two ongoing clinical trials at all times, the attainment of the funding conditions set forth in the agreement and covenants regarding financial reporting, limits on the Company's cash burn, incurrence of indebtedness, permitted investments, encumbrances, distributions, investments and mergers and acquisitions. The Loan is also secured by a security interest in all of the Company's personal property, excluding its intellectual property.
	In connection with the Loan, in August 2014, the Company issued Square 1 Bank a warrant, exercisable for 52,695 shares of the Company's common stock at an exercise price of $4.27. In accordance with ASC 480-10, Distinguishing Liabilities from Equity, the freestanding warrant for the Company's common stock was recognized as a liability and recorded at fair value in all periods prior to exercise. The warrant liability was re-measured to fair value prior to reclassification to additional paid in capital upon its exercise.  The initial fair value of the warrant of $323,021 was recorded as a liability and a discount to notes payable and is being amortized to interest expense over the term of the Loan. In September 2014, the warrants were exercised via a cashless exercise into 17,664 shares of the Company's common stock. The fair value of the warrants is shown as a debt discount and is netted against the outstanding loan balance in the consolidated balance sheets.
	As of December 31, 2014 future principal payments under the Company's notes payable agreement are as follows:
	Years ending December 31,
	2015	$	397,465
	2016		1,223,502
	2017		1,223,502
	2018		155,531
	Total	$	3,000,000

License_Agreements

License Agreements	12 Months Ended
	Dec. 31, 2014
License Agreements [Abstract]
License Agreements	9
	License Agreements
	On July 11, 2008, Heat entered into two agreements with The University of Miami (the “University”) to license, from the University, certain technology and processes in various stages of patent pursuit on an exclusive basis for use in its research and development and commercial activities (“License Agreement 03-31, 05-39” and “License Agreement 97-14”, or collectively “License Agreements”). Heat has the right to grant sublicenses under the License Agreements.
	Heat is also responsible for all patent costs, past and future, associated with the preparation, filing, prosecution, issuance, and maintenance of United States patent applications. Heat is also required to make minimum royalty payments to the University under the terms of the License Agreements.
	In connection with the License Agreements, Heat agreed to issue to the University 10% of all issued and outstanding common stock in each class and series on a fully-diluted basis together with rights to participate in future stock offerings.
	In April 2009, Heat and the University agreed to amend the original License Agreements of July 11, 2008 to extend the terms of payments. For the additional consideration of $12,500 and additional stock of 2.5% of fully-dilutable shares issued and outstanding for each License Agreement, a revised extension date of August 11, 2009 was granted for all past due license fees and patent costs. Furthermore, the 10% original stock holdings were given assurance of anti-dilution protection until a “Qualified Investment” pursuant to this agreement. This anti-dilution protection has been distinguished with the subsequent agreement described below.
	On June 26, 2009, Heat assigned all rights and obligations of License Agreement 97-14 to its subsidiary, Heat I. All previous stock ownership and rights of the University to participate in future stock offerings by Heat were mutually terminated. Heat I agreed to issue the University 5% of the subsidiary's issued and outstanding common stock in each class and series on a fully-diluted basis, together with fully-dilutable common shares equal to 2.5% of the total number of shares in each class and series issued outstanding. As a result, the University owns 7.5% of Heat I's issued and outstanding common stock. The Company agreed to make minimum royalty payments of $10,000 for three years beginning 2010 due on the anniversary date of the agreement. Beginning in 2013, and thereafter for the life of the agreement, the minimum royalty payment shall be $20,000 due on the same date. A milestone payment is due no later than May 2017 of $250,000 for License Agreement 97-14.
	In August 2009, Heat I and the University entered into a second amendment (“Amendment 2”) to License Agreement 97-14 to extend the foregoing payment due dates for all past due license fees and patent costs.
	On August 30, 2010, Heat entered into an option agreement with the University of Michigan (“University II”) to acquire the right to negotiate an exclusive license for certain materials which includes cancer bladder cells and all unmodified derivatives of these cells. An option fee of $2,000 was paid on September 8, 2010 to grant a period of nine months for this consideration. In July 2011, the Company exercised the option to acquire the license for $10,000.
	On February 18, 2011, Heat I entered into a license agreement (“SS114A”) with the University to obtain additional technology related to License Agreement 97-14. Heat I agreed to reimburse the University for all past patent costs of $37,381. As partial consideration for the license, Heat II agreed to grant back certain exclusive rights to the University.
	On February 18, 2011, Heat I entered into a license agreement (“143”) with the University to obtain additional technology related to License Agreement 97-14. In consideration for the license, Heat I agreed to pay the University a fee of $50,000 and reimburse them for past patent costs of $14,158.
	On February 18, 2011, Heat I entered into a license agreement (“J110”) with the University to obtain additional technology related to License Agreement 97-14. In consideration for the license, Heat I agreed to pay the University a fee of $10,000 and reimburse them for past patent costs of $1,055.
	On February 18, 2011, Heat I entered into a license agreement (“D-107”) with the University to obtain additional technology related to License Agreement 97-14.
	On April 12, 2011, Heat entered into a non-exclusive evaluation and biological material license agreement with a not-for-profit corporation for evaluation and production of vaccines. In consideration for the evaluation and commercial use license, Heat agreed to pay the not-for-profit corporation a fee of $5,000 and $50,000, respectively. Heat has the option to renew the license once the original term has expired.  Milestone payments are due upon certain events agreed upon by Heat and the not-for-profit corporation.
	At December 31, 2011, Heat owed the University $160,000 in unpaid license fees. At December 19, 2012, Heat I owed the University $102,784 in unpaid license fees. Heat entered into a payment agreement on December 19, 2012 to extend the payment due of Heat I obligations until the earlier of the closing of a Series B financing round or June 1, 2013.  As consideration for the extension of payment Heat I made an additional payment to the University equal to 18% annual interest of the outstanding balance on or before the due date or at the University's option convert into shares of preferred stock according to the terms stipulated in the agreement.
	On September 23, 2014, Heat entered into an exclusive license agreement for a multiple myeloma cell line with Professor Kenneth Nilsson in Sweden. In consideration of the commercial license, Heat agreed to pay an up-front license fee of $5,000 and are obligated to pay an annual maintenance fee of $3,000 each year until the first commercial sale of a licensed product at which time the annual maintenance fee increases to $30,000. Milestone payments are due upon certain events agreed upon by Heat and Professor Kenneth Nilsson.
	In addition, Heat entered into an agreement with the University of Miami in September 2014 for a cancer cell line where the University agreed not to license the cell line to third parties while we are in good standing and in compliance of our patent license agreements with the University relating to our ImPACT™ platform. There are no financial obligation on our part under the arrangement.
	Future minimum royalty payments as of December 31, 2014 are as follows:
	Year ended December 31,
	2015	$	33,000
	2016		33,000
	2017		283,000
	2018		33,000
	2019		33,000
	Thereafter		99,000
	Total	$	514,000

Stock_Warrants_Liability

Stock Warrants Liability	12 Months Ended
	Dec. 31, 2014
Stock Warrants Liability [Abstract]
Stock Warrants Liability	10
	Stock Warrants Liability
	The summary of stock warrants liability activity for the years ended December 31, 2014 and 2013 is as follows:
		Number of			Weighted		Weighted		Weighted
		Warrants			Average		Average		Average
					Exercise		Remaining		Fair Value
					Price		Contractual
							Life (in years)
	Outstanding at December 31, 2012		20,549		$	4.83		8.9	$	1.64
	Granted		—			—		—		—
	Exercised		—			—		—		—
	Expired/cancelled		—			—		—		—
	Outstanding at December 31, 2013		20,549		$	4.83		8.2	$	5.95
	Granted		52,695		$	4.27		10	$	6.13
	Exercised		(73,244	)	$	4.43		9.5	$	6.08
	Expired/cancelled		—			—		—		—
	Outstanding at December 31, 2014		—		$	—		—	$	—
	The aggregate intrinsic value of the stock warrants in the table above is $0 and $46,646 at December 31, 2014 and 2013, respectively. The aggregate intrinsic value is before applicable income taxes and is calculated based on the difference between the exercise price of the warrants and the estimated fair market value of the Company's common stock as of the respective dates.

Stockholders_Equity_Deficit

Stockholders' Equity (Deficit)

12 Months Ended

Dec. 31, 2014

Stockholders' Equity [Abstract]

Stockholders' Equity

11

Stockholders' Equity

Authorized Capital

Heat has authorized 2,000,000 shares of Series A Preferred Stock (par value $0.0001) as of December 31, 2014 and 2013. No Series A Preferred Stock was outstanding at December 31, 2013 and 2014. In 2013, Heat authorized 4,100,000 shares of Series B Preferred Stock (par value $0.0002). In March 2013, the Company sold an aggregate of 1,891,419 shares of the Company's Series B-1 Preferred Stock for gross proceeds of approximately $5.0 million in our Series B Preferred Stock private placement. All shares of the Series B Preferred Stock, together with accrued dividends, automatically converted into shares of the Company's common stock upon the consummation of the Company's initial public offering on July 29, 2013. In addition, the investors in the Series B-1 Preferred Stock were issued shares of the Company's common stock having a value based upon the initial public offering price of $361,668 and the Company's obligation to issue, and the investors, obligation to purchase, Series B-2 Preferred Stock and warrants upon fulfillment of certain conditions specified in the Company's stock purchase agreement dated as of March 25, 2013 entered into in connection with such private placement (the “Stock Purchase Agreement”) terminated. As of December 31, 2014 and 2013 there were no outstanding shares of Preferred Stock.

Heat had 50,000,000 shares of common stock (par value $0.0002) authorized as of December 31, 2014 and 2013. Of the 50,000,000 common stock shares, 6,492,622 and 6,375,426 were issued and outstanding as of December 31, 2014 and 2013, respectively.

Preferred Stock

Series A, Series B-1, and Series B-2

Automatic Conversion

Each share of Preferred Stock automatically converts to common stock upon the earlier to occur of (i) on the date of consummation of a sale of common stock in a firm commitment underwritten public offering resulting in aggregate net cash proceeds to the Company (after deducting applicable underwriting discounts and commissions) of at least $15 million net proceeds; (ii) with respect to the Series A Preferred Stock, if 2/3 of the Series A Preferred Stock holders (including one of the larger investors so long as they hold 40% of the Series A Preferred Stock) vote in favor of a conversion then the Series A will automatically convert to common stock; and (iii) with respect to the Series B Preferred Stock if 2/3 of the Series B Preferred Stock holders vote in favor of a conversion then the Series B will automatically convert to common stock. As a result of the IPO, all outstanding shares of preferred stock were automatically converted to common stock.

Optional Conversion

The preferred stock is convertible into common stock at the option of the holder at any time. The conversion ratio for each share of the Series A Preferred Stock was its Original Issue Price ($2.10 for each share of the Series A Preferred Stock) divided by its Conversion Price, as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like, which Conversion Price initially was the Original Issue Price. The conversion ratio for each share of the Series B-1 Preferred Stock and the Series B-2 Preferred Stock was its Original Issue Price ($2.67 and $5.00 for each share of the Series B-1 Preferred Stock and Series B-2 Preferred Stock, respectively) plus accrued but unpaid dividends thereon divided by its conversion price, as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like, which conversion price initially was the Original Issue Price. As a result of the 1-for-2.3 reverse stock split, the conversion ratio for the Preferred Stock was 0.4348.

In the event the Company at any time or from time to time after the Initial Series B Issuance Date shall issue additional shares of common stock without consideration or for consideration per share less than the Series A Conversion Price, Series B-1 Conversion Price, or Series B-2 Conversion Price, in effect on the date of and immediately prior to such issue, then the Series A Conversion Price, the Series B-1 Conversion Price, Series B-2 Conversion Price, shall be reduced, to a price determined by multiplying the Series A Conversion Price, the Series B-1 Conversion Price, or the Series B-2 Conversion Price in effect by a fraction, (A) the numerator of which shall be the number of shares of common stock outstanding immediately prior to such issuance, on a fully-diluted basis, plus the number of shares of common stock which the aggregate consideration received by the Company for the total number of Additional Shares of Common Stock so issued would purchase at the Series A Conversion Price, the Series B-1 Conversion Price, or the Series B-2 Conversion Price, as in effect immediately prior to such issuance, and (B) the denominator of which shall be the number of shares of common stock outstanding immediately prior to such issuance, on a fully-diluted basis, plus the number of such Additional Shares of common stock so issued. As a result of the IPO, all outstanding shares of preferred stock were automatically converted to common stock.

The preferred stock was determined to have characteristics more akin to equity than debt. Particularly, the preferred stock had no mandatory redemption provision nor was it redeemable at the option of the holder. As a result, the conversion option was determined to be clearly and closely related to the preferred stock and therefore did not need to be bifurcated and classified as a liability.

Dividends

The Series B Preferred Stock has a priority with respect to dividend distributions and distributions upon liquidation. The Series B Preferred Stock receive dividends when and as and if declared by the Board at a rate of 5% of their original issue price of such shares which is $6.14 per share for the Series B-1 Preferred Stock and $11.50 per share for the Series B-2 Preferred Stock. If the Company declares or pays a dividend upon the common stock, they must also pay to the holders of the Series A and B Preferred Stock the dividends that would have been declared with respect to common stock issuable upon conversion of the Series A and B Preferred Stock; provided, however that the Company cannot declare or pay a dividend unless and until all accrued dividends on the Series B Preferred Stock have been paid.

Liquidation

In the event of a liquidation, the holders of the Series B-1 and B-2 Preferred Stock are entitled to receive before any payment to any other Preferred Stockholder or common stock holder an amount per share equal to the greater of $6.14 for the Series B-1 Preferred Stock and $11.50 for the Series B-2 Preferred Stock plus any dividends accrued and unpaid whether or not declared. After payment in full of the Series B Preferred Stockholders the holders of the Series A Preferred Stock are entitled to receive before any payment to the common stock holder an amount per share equal to $4.83 plus any dividends declared but unpaid. After the payment in full of the amounts set forth above, the Company's assets will be distributed ratably to all holders of common stock and Series B Preferred Stock on an as converted basis except that the Series B Preferred Stockholders shall not continue to share in such distribution after each has received 3 times its Original Issue Price.

Voting Rights

Each holder of Preferred Stock is entitled to vote on all matters stockholders are entitled to vote and to cast the number of votes as shall equal the whole number of shares of common stock into which their shares of Preferred Stock are convertible.

Initial Public Offering

On July 29, 2013, the Company sold 2,500,000 shares of common stock at a public offering price of $10.00 per share upon the closing of the Company's initial public offering (“IPO”) with gross proceeds of $25 million and net proceeds of $22.4 million. On August 15, 2013, the Company sold an additional 100,000 shares of common stock at a public offering price of $10.00 per share pursuant to the partial exercise of the over-allotment option granted to the underwriters resulting in additional gross proceeds to the Company of $1,000,000 and additional net proceeds of $930,000. On September 6, 2013, the Company sold an additional 100,000 shares of common stock at a public offering price of $10.00 per share pursuant to the partial exercise of the over-allotment option granted to the underwriters resulting in additional gross proceeds to the Company of $1,000,000 and additional net proceeds of $930,000. The total gross proceeds raised from the offering and over-allotment option were $27,000,000, before underwriting discounts, commissions and other offering expenses payable by the Company. The total net proceeds from the offering were approximately $24.3 million. Upon the closing of the IPO, all shares of the Company's then-outstanding preferred stock automatically converted into an aggregate of 1,696,683 shares of common stock. In addition, upon the closing of the IPO, the Company issued an additional 36,167 shares of common stock to the Series B Preferred Stockholders as a Preferred Stock dividend. This transaction is discussed above under “Preferred Stock Dividend”. At that time, the Company's obligation to issue, and the Series B Preferred Stockholders' obligation to purchase Series B-2 Preferred Stock under the Stock Purchase Agreement terminated.

Restricted Stock

As of December 31, 2014 and 2013, all restricted stock has vested and accordingly all stock-based compensation expense related to vested restricted stock has been recognized.

Common Stock Warrants

In December 2011 and August 2012, the Company issued 20,549 warrants to lenders that were originally exercisable into Series A Preferred stock. The warrants had an expiration period of 10 years and converted from preferred stock warrants into warrants to purchase common stock at an exercise price of $4.83 per share upon the completion of the initial public offering in July 2013. In January and February 2014, all 20,549 warrants were exercised in cashless transactions that resulted in the issuance of 8,065 shares of common stock.

On March 10, 2011, the Company issued warrants to purchase 32,610 shares of common stock to non-employee placement agents in consideration for a private equity placement transaction. The warrants have an exercise price of $0.48 per share and expire 10 years from the issuance date. These warrants do not meet the criteria required to be classified as liability awards and therefore they are treated as equity awards. In February 2014, 15,218 warrants were exercised in cashless transactions that resulted in the issuance of 14,318 shares of common stock.

In connection with our initial public offering, the Company issued warrants to the underwriters for 125,000 shares of common stock issuable at $12.50 per share upon exercise. The warrants have a five-year life and expire on July 23, 2018. These warrants do not meet the criteria required to be classified as liability awards and therefore they are treated as equity awards.

In connection with the Loan, in August 2014, the Company issued Square 1 Bank a warrant, exercisable for 52,695 shares of the Company's common stock at an exercise price of $4.27. In September 2014, the warrants were exercised via a cashless exercise into 17,664 shares of the Company's common stock.

The following table summarizes the activity of the Company's common stock warrants, retroactively adjusted for the 1-for-2.3 reverse stock split.

Common Stock

Warrants

Outstanding, December 31, 2012

53,159

Granted to underwriters

125,000

Exercised

—

Expired

—

Outstanding, December 31, 2013

178,159

Granted to lenders

52,695

Exercised

(88,462

)

Expired

—

Outstanding, December 31, 2014

142,392

The weighted average exercise price of 142,392 outstanding warrants as of December 31, 2014 is $11.03.

Equity Compensation Plan

2009 Stock Incentive Plan

In 2009, the Company adopted the 2009 Stock Option Plan of Heat Biologics, Inc. (the “2009 Plan”), under which stock options to acquire 217,391 common shares could be granted to key employees, directors, and independent contractors.  Under the 2009 Plan, both incentive and non-qualified stock options could be granted under terms and conditions established by the Board of Directors. The exercise price for incentive stock options was the fair market value of the related common stock on the date the stock option was granted. Stock options granted under the 2009 Plan generally have terms of 10 years and have various vesting schedules.

The Company amended the 2009 Stock Option Plan and all related addendum agreements in April 2011. This second amendment increased the number of shares available for issuance from 217,391 to 652,174. The Company amended the 2009 Plan to increase the number of shares available for issuance to 869,565. As of December 31, 2014 and 2013, there were 581,842 and 633,482 stock options outstanding under the 2009 Plan, respectively.

2014 Stock Incentive Plan

In June 2014, the stockholders approved the 2014 Stock Option Plan of Heat Biologics, Inc. (the “2014 Plan”), under which the Company is authorized to grant 500,000 awards in the form of both incentive and non-qualified stock options, restricted stock, stock appreciation rights and other stock based awards on terms established by the Compensation Committee of the Board of Directors which has been appointed by the Board of Directors to administer the 2014 Plan. Persons eligible to participate in the 2014 Plan include employees, directors, and consultants. Stock options granted under the 2014 Plan generally have terms of 10 years and have various vesting schedules.

The 2014 Plan supplements the Company's 2009 Stock Incentive Plan (the “2009 Plan”) under which the Company is authorized to grant 500,000 awards in the form of options, restricted stock, restricted stock units and other stock based awards. As of December 31, 2014, there were 436,748 stock options outstanding under the 2014 Plan.

As of December 31, 2014, awards for 1,416,091 shares of common stock have been granted and 115,398 shares had been forfeited under the 2009 and 2014 Plans (“the Plans), of which 1,018,590 are outstanding, leaving 68,872 shares of common stock remaining available for grant under the Plans. The following table summarizes the components of the Company's stock-based compensation included in net loss:

For the years ended

December 31,

2014

2013

Employee stock options

$

570,760

$

131,178

Non-employee stock options

495,683

415,212

Restricted stock awards

—

25,534

$

1,066,443

$

571,924

Stock Options

The fair value of each stock option is estimated on the date of grant using the Black-Scholes-Merton option pricing model with the following assumptions for stock options granted during the years ended:

December 31,

2014

2013

Dividend yield

0

%

0

%

Expected volatility

107-110

%

90-112

%

Risk-free interest rate

2.06-2.23

%

1.39-2.26

%

Expected lives (years)

5.9-6.5

5.75-6.5

The risk-free interest rate is based on U.S. Treasury interest rates at the time of the grant whose term is consistent with the expected life of the stock options. The Company used an average historical stock price volatility based on an analysis of reported data for a peer group of comparable companies that have issued stock options with substantially similar terms, as the Company did not have any trading history for its common stock. Expected term represents the period that the Company's stock option grants are expected to be outstanding. The Company elected to utilize the “simplified” method to estimate the expected term. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option.

Expected dividend yield was considered to be 0% in the option pricing formula since the Company had not paid any dividends and had no plans to do so in the future. The forfeiture rate was considered to be none insofar as the historical experience of the Company is very limited. As required by ASC 718, the Company will adjust the estimated forfeiture rate based upon actual experience.

The Company recognized $1,066,443 and $571,924 in stock-based compensation expense for the years ended December 31, 2014 and 2013, respectively for the Company's stock option awards.

The following tables summarize the stock option activity for the years ended December 31, 2013 and 2014:

Shares

Weighted

Average

Exercise

Price

Outstanding, December 31, 2012

590,047

$

0.71

Granted

186,736

$

10.07

Exercised

(80,706

)

$

0.67

Forfeited

(62,595

)

$

1.96

Outstanding, December 31, 2013

633,482

$

3.36

Granted

507,879

$

6.3

Exercised

(78,664

)

$

0.6

Forfeited

(44,107

)

$

3.19

Outstanding, December 31, 2014

1,018,590

$

5.04

The weighted average grant-date fair value of stock options granted during the years ended December 31, 2014 and 2013 was $5.66 and $8.51, respectively.

The total fair value of stock options that vested during the year ended December 31, 2014 was approximately $1,704,121.

The following table summarizes information about stock options outstanding at December 31, 2014:

Options Outstanding

Options Exercisable

Options Vested or Expected to Vest

Balance

Weighted

Weighted

Balance

Weighted

Weighted

Balance

Weighted

Weighted

as of

Average

Average

as of

Average

Average

as of

Average

Average

12/31/14

Remaining

Exercise

12/31/14

Remaining

Exercise

12/31/14

Remaining

Exercise

Contractual

Price

Contractual

Price

Contractual

Price

Life

Life

Life

(Years)

(Years)

(Years)

1,018,590

7.81

$5.04

473,696

5.99

$2.67

473,696

5.99

$2.67

As of December 31, 2014, the unrecognized stock-based compensation expense related to unvested stock options was approximately $3,872,221 that is expected to be recognized over a weighted average period of approximately 14.9 months.

Income_Tax

Income Tax	12 Months Ended
	Dec. 31, 2014
Income Tax [Abstract]
Income Tax	12
	Income Tax
	The components of income tax expense (benefit) attributable to continuing operations are as follows:
		Years ended December 31,
		2014			2013
	Current expense:
	Federal	$	—		$	—
	State		—			—
	Deferred expense (benefit):
	Federal	$	—		$	—
	State		—			—
	Total	$	—		$	—
	The differences between the Company's consolidated income tax expense attributable to continuing operations and the expense computed at the 34% United States statutory income tax rate were as follows:
		Years ended December 31,
		2014			2013
	Federal income tax expense at statutory rate	$	(4,162,691	)	$	(2,247,353	)
	State and local income taxes, net of federal benefit		(344,247	)		(186,475	)
	Non-deductible expenses		239,213			4,985
	Prior-period true-up		(161,018	)		162,061
	Research & development credit		(454,031	)		(180,687	)
	Change in tax rate		—			32,774
	Stock based compensation		135,008			—
	Increase in valuation allowance		4,747,766			2,414,695
		$	—		$	—
	The income tax effects of temporary differences from continuing operations that give rise to significant portions of deferred income tax assets (liabilities) are presented below:
		December 31,
		2014			2013
	Deferred tax assets:
	Net operating loss carryforward	$	8,141,857		$	4,167,785
	Research & development credit		961,445			424,739
	Other		484,954			247,966
	Valuation allowance		(9,588,256	)		(4,840,490	)
	Deferred income taxes	$	—		$	—
	During 2014, the Company's valuation allowance increased by $4,747,766. This increase was primarily due to the generation of additional net operating loss carryforwards and income tax credits.
	The Company has approximately $42,039,675 of federal and state operating loss carryforwards which begin to expire in 2023.
	In accordance with FASB ASC 740, Accounting for Income Taxes, the Company reflects in the financial statements the benefit of positions taken in a previously filed tax return or expected to be taken in a future tax return only when it is considered ‘more-likely-than-not' that the position taken will be sustained by a taxing authority. As of December 31, 2014 and 2013, the Company had no unrecognized income tax benefits and correspondingly there is no impact on the Company's effective income tax rate associated with these items. The Company's policy for recording interest and penalties relating to uncertain income tax positions is to record them as a component of income tax expense in the accompanying statements of income. As of December 31, 2014 and 2013, the Company had no such accruals.
	The Company files income tax returns in the United States and various state jurisdictions. The Company is subject to examination by taxing authorities for the tax years ended December 31, 2008 through 2013.

Related_Party

Related Party	12 Months Ended
	Dec. 31, 2014
Related Party [Abstract]
Related Party	13
	Related Party
	A member of the Company's management was paid $28,000 and $34,480 in consulting fees for the years ended December 31, 2014 and 2013, respectively.
	The Company compensates its board members. Board members received between $32,000 and $37,000 and between $5,000 and $10,870 for services rendered during 2014 and 2013, respectively. Board members were not compensated prior to the Company's initial public offering in 2013.
	The Company had a related party payable balance of $26,750 and $13,000 as of December 31, 2014 and 2013, respectively.
	The Company had a related party receivable balance of $48,642 and $24,946 as of December 31, 2014 and 2013, respectively.

Net_Loss_Per_Share

Net Loss Per Share	12 Months Ended
	Dec. 31, 2014
Net Loss Per Share [Abstract]
Net Loss Per Share	14
	Net Loss Per Share
	Basic net loss per common share is computed by dividing net loss applicable to common stockholders by the weighted-average number of common shares outstanding during the periods. Fully diluted net loss per common share is computed using the weighted average number of common and dilutive common equivalent shares outstanding during the periods. Common equivalent shares consist of stock options and warrants that are computed using the treasury stock method.
	For the years ended December 31, 2014 and 2013, all of the Company's common stock options and warrants are anti-dilutive and therefore have been excluded from the diluted calculation.
	The following table reconciles net loss to net loss applicable to common stockholders:
		For the years ended
		December 31,
		2014				2013
	Net loss	$	(12,243,211	)		$	(6,609,864	)
	Net loss: Non-controlling interest		(454,394	)			(198,516	)
	Beneficial conversion charge		—				(2,300,000	)
	Preferred Stock Dividend		—				(361,668	)
	Net loss applicable to common stockholders	$	(11,788,817	)		$	(9,073,016	)
	Weighted-average number of common shares used in net loss per share applicable to common stockholders—basic and diluted		6,454,866				3,747,357
	Net loss per share applicable to common stockholders—basic and diluted	$	(1.83	)		$	(2.42	)
	The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect):
		For the years ended
		December 31,
		2014			2013
	Outstanding stock options		1,018,590			633,482
	Common stock warrants		142,392			178,159
	Reverse Stock Split
	In May 2013, the Company's board of directors and stockholders approved a 1-for-2.3 reverse stock split of the Company's common stock. The reverse stock split became effective on May 29, 2013. All share and per share amounts in the financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split, including reclassifying an amount equal to the increase in par value to additional paid-in capital.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies [Abstract]
Commitments and Contingencies	15
	Commitments and Contingencies
	On January 24, 2014 the Company entered into a five year lease for 5,303 square feet of office and laboratory space for monthly rent of $10,341 exclusive of payments required for maintenance of common areas and utilities. On September 30, 2014 the lease was amended to expand the premises by an additional 676 square feet for a total of 5,979 square feet for a monthly rent of $11,638. Based on the Company's current operational plans, the Company believes that such facilities are adequate for operations for the near future. Prior to January 2014, the Company leased approximately 2,111 square feet of office space for monthly rent of $4,046. Rent expense was $100,973 and $48,377, for the years ended December 31, 2014 and 2013, respectively.  The Company's approximate future minimum payments for its operating lease obligations that have initial remaining non-cancelable terms in excess of one year are as follows:
	Years ending December 31,
	2015	$	192,833
	2016		218,271
	2017		224,282
	2018		231,010
	2019		194,401
	Total	$	1,060,797

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	16
	Subsequent Events
	Departure of Certain Officers and Appointment of Certain Officers
	On March 9, 2015 the Company entered into a Severance Agreement (the “Severance Agreement”) with Matthew Czajkowski, the Company's Chief Financial Officer effective March 15, 2015. The complete terms of the Severance Agreement is filed as Exhibit 10.1 to Form 8-K filed March 11, 2015. Mr. Czajkowski has the ability to exercise all stock options issued to him that vested prior to the date of resignation at any time prior to the ten year anniversary of the date of grant and any unvested options at the time of resignation were immediately vested and are exercisable for 90 days after March 15, 2015.
	On March 9, 2015, the Company entered into a consulting agreement (the “Consulting Agreement”) with Danforth Advisors, LLC (“Danforth”), pursuant to which Danforth will provide finance, accounting and administrative functions, including interim chief financial officer services to be provided by Mr. Stephen J. DiPalma. The Company will pay Danforth an agreed upon hourly rate for such services and will reimburse Danforth for expenses. The Consulting Agreement will continue until December 31, 2015 and may be extended by mutual agreement of the parties. The Consulting Agreement may be terminated by the Company with cause immediately and without cause, upon 30 days written notice.
	Public Offering
	On March 10, 2015, the Company entered into an Underwriting Agreement (the “Underwriting Agreement”) with Aegis Capital Corp. (“Aegis”), as representative of the several underwriters named therein (the “Underwriters”), providing for the offer and sale in a firm commitment underwritten public offering (the “Offering”) of 1,640,000 shares of the Company's common stock, and 246,000 additional shares of the common stock to cover over-allotments at an offering price of $6.50 per share. The net proceeds to the Company from the Offering were approximately $11.1 million, after deducting underwriting discounts and commissions and other estimated offering expenses. The Underwriting Agreement contains customary representations, warranties, and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended (the “Securities Act”), other obligations of the parties and termination provisions. The Underwriting Agreement Agreement is filed as Exhibit 1.1 to the Form 8-K filed March 12, 2015.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2014

Summary of Significant Accounting Policies [Abstract]

Basis of Accounting

Basis of Accounting

The accompanying consolidated financial statements have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Principles of Consolidation

Principles of Consolidation

The consolidated financial statements include the accounts of Heat Biologics, Inc. and its subsidiaries, Heat Biologics I, Inc. (“Heat I”) Heat Biologics III, Inc. (“Heat III”), Heat Biologics IV, Inc. (“Heat IV”), Heat Biologics GmbH and Heat Biologics Australia Pty Ltd. All significant intercompany accounts and transactions have been eliminated in consolidation. At December 31, 2014 and 2013, Heat held a 92.5% controlling interest in Heat I and accounts for its less than 100% interest in the consolidated financial statements in accordance with U.S. GAAP. Accordingly, the Company presents non-controlling interests as a component of stockholders' equity  on its consolidated balance sheets and reports non-controlling interest net loss under the heading “net loss – non-controlling interest” in the consolidated statements of operations.

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Estimates are used for, but not limited to, useful lives of fixed assets, income taxes and stock-based compensation. Actual results may differ from those estimates.

Cash and Cash Equivalents and Restricted Cash

Cash and Cash Equivalents and Restricted Cash

The Company considers all cash and other highly liquid investments with initial maturities from the date of purchase of three months or less to be cash and cash equivalents. The Company had a restricted cash balance of $101,129 and $1,252 at December 31, 2014 and 2013, respectively. The United States Patent and Trade Office (“USPTO”) requires the Company to maintain an account with a minimum of $1,000 to be used to pay fees associated with new trademarks of the Company and one of the Company's lenders required a minimum $100,000 cash balance to be maintained with the lending bank to secure the Company credit card during 2014.

Concentration of Credit Risk

Concentration of Credit Risk

At times, cash balances may exceed the Federal Deposit Insurance Corporation (“FDIC”) insurable limits. The Company has never experienced any losses related to these balances. As of December 31, 2014 and 2013, cash amounts in excess of $250,000 were not fully insured. The uninsured cash balance as of December 31, 2014 was $3,704,026. The Company does not believe it is exposed to significant credit risk on cash and cash equivalents.

Deferred Financing Costs, net

Deferred Financing Costs, net

Deferred financing costs, net include the costs incurred to obtain financing and are amortized using the straight-line method, which approximates the effective interest method, over the life of the related debt. Deferred financing costs, net are included in the accompanying consolidated balance sheets net of amortization.

Property and Equipment

Property and Equipment

Property and equipment are stated at cost and are capitalized if the cost exceeds $500. Depreciation is calculated using the straight-line method and is based on estimated useful lives of five years for lab equipment and computer equipment, and seven years for furniture and fixtures.

Stock Warrants Liability

Stock Warrants Liability

In 2012 and 2013, the Company issued warrants exercisable for a total of 20,549 shares of common stock. The freestanding warrants for the Company's common stock were recognized as a liability and recorded at fair value in all periods prior to exercise. Upon the cashless exercise of these warrants in January and February 2014, the sum of the fair value of the exercised warrants were credited to additional paid in capital and the liability was eliminated.

In connection with the Square 1 Bank Loan (“Loan”), in August 2014, the Company issued Square 1 Bank a warrant, exercisable for 52,695 shares of the Company's common stock at an exercise price of $4.27. In accordance with ASC 480-10, Distinguishing Liabilities from Equity, the freestanding warrant for the Company's common stock was recognized as a liability and recorded at fair value in all periods prior to exercise. The warrant liability was re-measured to fair value prior to reclassification to additional paid in capital upon its exercise.  The initial fair value of the warrant of $323,021 was recorded as a liability and a discount to notes payable and is being amortized to interest expense over the term of the note. In September 2014, the warrants were exercised via a cashless exercise into 17,664 shares of the Company's common stock.

The fair value of the warrants was calculated using the Black-Scholes option pricing model with the following assumptions:

December 31,

2014

2013

Risk-free interest rate

2.23-2.46

%

2.75

%

Expected volatility

73.0-100

%

71.6-71.9

%

Expected life (years)

7.8-10

7.96-8.6

Expected dividend yield

0

%

0

%

The Company had no stock warrant liability as of December 31, 2014.

Beneficial Conversion Feature

Beneficial Conversion Feature

When the Company issues an equity security that is convertible into common stock at a discount from the fair value of the common stock at the date the equity security counterparty is legally committed to purchase such a security (Commitment Date), a beneficial conversion charge is measured and recorded on the Commitment Date for the difference between the fair value of the Company's common stock and the effective conversion price of the equity security. If the intrinsic value of the beneficial conversion feature is greater than the proceeds allocated to the equity security, the amount of the discount assigned to the beneficial conversion feature is limited to the amount of the proceeds allocated to the equity.

The amount allocated to the beneficial conversion feature is presented as an immediate charge to earnings available to common stockholders for convertible preferred stock instruments that are convertible by the stockholders at any time. In connection with the Company's issuance of Series B-1 Preferred Stock during fiscal year 2013, the Company recorded a beneficial conversion charge of $2.3 million representing the difference between the effective conversion price of $6.14 and the fair value of the Company's common stock as of the Commitment Date of $8.81.

Net Loss per Share

Net Loss per Share

Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during each year. Fully diluted net loss per share is computed using the weighted average number of common shares and dilutive securities outstanding during each year. Dilutive securities having an anti-dilutive effect on diluted loss per share are excluded from the calculation.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

The carrying amount of certain of the Company's financial instruments, including cash and cash equivalents, prepaid expenses and other current assets, deposits, accounts payable and accrued expenses and other payables approximate fair value due to their short maturities. The carrying value of debt approximates fair value because the interest rate under the obligation approximates market rates of interest available to the Company for similar instruments.

As a basis for determining the fair value of certain of the Company's financial instruments, the Company utilizes a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

Level I – Observable inputs such as quoted prices in active markets for identical assets or liabilities.

Level II – Observable inputs, other than Level I prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level III – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The Company's financial instruments that are measured at fair value on a recurring basis consist only of the stock warrants liability. The Company's stock warrants liability was classified within Level III of the fair value hierarchy and as of December 31, 2014 and 2013.

The change in the fair value of the Level III warrants liability is summarized below:

Fair value at December 31, 2012

$

92,150

Change in fair value during the period

30,440

Fair value at December 31, 2013

122,590

Issuance of new warrants

323,021

Change in fair value during the period

7,263

Cashless exercise during the period

(452,874

)

Fair value at December 31, 2014

$

—

There were no assets or liabilities measured at fair value on a recurring basis as of December 31, 2014. The liabilities measured at fair value on a recurring basis as of December 31, 2013 are summarized below:

31-Dec-13

Identical

Observable

Unobservable

Total

Assets

Inputs

Inputs

December 31,

Description

(Level 1)

(Level 2)

(Level 3)

2013

Liabilities measured at fair value

Stock Warrant Liability

$

—

$

—

$

(122,590

)

$

(122,590

)

Total Liabilities measured at fair value

$

—

$

—

$

(122,590

)

$

(122,590

)

Marketing

Marketing

Marketing costs are expensed as incurred. Marketing expense totaled $135,372 and $135,366 for the years ended December 31, 2014 and 2013, respectively.

Income Tax

Income Tax

Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying amounts of assets and liabilities and their respective tax bases, operating loss carryforwards, and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

In accordance with FASB ASC 740, Accounting for Income Taxes, the Company reflects in the financial statements the benefit of positions taken in a previously filed tax return or expected to be taken in a future tax return only when it is considered ‘more-likely-than-not' that the position taken will be sustained by a taxing authority. As of December 31, 2014 and 2013, the Company had no unrecognized income tax benefits and correspondingly there is no impact on the Company's effective income tax rate associated with these items. The Company's policy for recording interest and penalties relating to uncertain income tax positions is to record them as a component of income tax expense in the accompanying consolidated statements of operations. As of December 31, 2014 and 2013, the Company had no such accruals.

Stock-Based Compensation

Stock-Based Compensation

The Company accounts for stock-based compensation arrangements with employees and non-employee directors using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments, including stock options. The fair value method requires the Company to estimate the fair value of stock-based payment awards on the date of grant using an option pricing model.

Stock-based compensation costs are based on the fair value of the underlying option calculated using the Black-Scholes-Merton option pricing model on the date of grant for stock options and recognized as expense on a straight-line basis over the requisite service period, which is the vesting period. Determining the appropriate fair value model and related assumptions requires judgment, including estimating stock price volatility, forfeiture rates and expected term. The expected volatility rates are estimated based on the actual volatility of comparable public companies over the expected term. The expected term for the years ended December 31, 2014 and 2013 represents the average time that options are expected to be outstanding based on the mid-point between the vesting date and the end of the contractual term of the award. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company has not paid dividends and does not anticipate paying a cash dividend in the foreseeable future and, accordingly, uses an expected dividend yield of zero. The risk-free interest rate is based on the rate of U.S. Treasury securities with maturities consistent with the estimated expected term of the awards. The measurement of nonemployee share-based compensation is subject to periodic adjustments as the underlying equity instruments vest and is recognized as an expense over the period over which services are received.

Net loss attributable to non-controlling interests

Net loss attributable to non-controlling interests

Net loss attributable to non-controlling interests is the result of the Company's consolidation of subsidiaries of which it does not own 100%. The Company's net loss attributable to non-controlling interests relates to the University's ownership in Heat I, for the years ended December 31, 2014 and 2013.

Revenue Recognition

Revenue Recognition

The Company recognizes government grants when there is reasonable assurance that they will comply with the conditions attached to the grants and the grants will be received. The grants are recognized using an income approach and grant revenue is recognized as the related expenses are incurred.

Research and Development

Research and Development

Research and development costs are expensed as incurred. The Company has acquired exclusive licensing rights to intellectual property to further its research and development. These costs are expensed as incurred. The Company also incurs intellectual property costs relating to the filing and application fees for patents which are owned by the universities with which the Company has license agreements. These costs are also expensed as research and development expense as incurred.

Impact of recently issued Accounting Standards

Impact of recently issued Accounting Standards:

In July 2014, the FASB issued Accounting Standards Update (“ASU”) ASU No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. The amendments in this ASU remove all incremental financial reporting requirements from U.S. GAAP for development stage entities, including the removal of Topic 915, Development Stage Entities, from the FASB Accounting Standards Codification™. A development stage entity is one that devotes substantially all of its efforts to establishing a new business and for which: (a) planned principal operations have not commenced; or (b) planned principal operations have commenced, but have produced no significant revenue. Current U.S. GAAP requires a development stage entity to present the same basic financial statements and apply the same recognition and measurement rules as established companies. In addition, U.S. GAAP requires a development stage entity to present inception-to-date information about income statement line items, cash flows, and equity transactions. For public business entities, the presentation and disclosure requirements in Topic 915 will no longer be required for the first annual period beginning after December 15, 2014. The revised consolidation standards are effective one year later, in annual periods beginning after December 15, 2015. Early adoption is permitted for financial statements that have not yet been issued or made available for issuance. The Company has elected to adopt the guidance as of June 30, 2014. The adoption did not impact the Company's financial position or results of operations.

In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (“ASU 2014-15”). The amendments in ASU 2014-15 are intended to define management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. Under GAAP, financial statements are prepared under the presumption that the reporting organization will continue to operate as a going concern, except in limited circumstances. The going concern basis of accounting is critical to financial reporting because it establishes the fundamental basis for measuring and classifying assets and liabilities. Currently, GAAP lacks guidance about management's responsibility to evaluate whether there is substantial doubt about the organization's ability to continue as a going concern or to provide related footnote disclosures. This ASU provides guidance to an organization's management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations today in the financial statement footnotes. This update is effective for annual periods ending after December 15, 2016, and interim periods within annual periods beginning after December 15, 2016. Early application is permitted for annual or interim reporting periods for which the financial statements have not previously been issued. We do not expect this ASU to have an impact on its consolidated financial statements.

In January 2015, the FASB issued ASU No. 2015-1, Income Statement - Extraordinary and Unusual Items. ASU 2015-01 will eliminate from U.S. GAAP the concept of extraordinary items and will no longer require an entity to separately classify, present, and disclose extraordinary events and transactions. ASU 2015-01 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015, and early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption. The Company does not believe the adoption of this guidance will have a material impact on its consolidated financial statements or related footnote disclosures.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Summary of Significant Accounting Policies [Abstract]
Schedule of Significant Assumptions Used in Valuing Stock Warrants Liability
		December 31,
		2014			2013
	Risk-free interest rate		2.23-2.46	%		2.75	%
	Expected volatility		73.0-100	%		71.6-71.9	%
	Expected life (years)		7.8-10			7.96-8.6
	Expected dividend yield		0	%		0	%
Schedule of Change in Fair Value of Level III Warrants Liability
	Fair value at December 31, 2012	$	92,150
	Change in fair value during the period		30,440
	Fair value at December 31, 2013		122,590
	Issuance of new warrants		323,021
	Change in fair value during the period		7,263
	Cashless exercise during the period		(452,874	)
	Fair value at December 31, 2014	$	—
Schedule of liabilities measured at fair value on a recurring basis		31-Dec-13
		Identical			Observable			Unobservable			Total
		Assets			Inputs			Inputs			December 31,
	Description	(Level 1)			(Level 2)			(Level 3)			2013
	Liabilities measured at fair value
	Stock Warrant Liability	$	—		$	—		$	(122,590	)	$	(122,590	)
	Total Liabilities measured at fair value	$	—		$	—		$	(122,590	)	$	(122,590	)

Investments_Tables

Investments (Tables)	12 Months Ended
	Dec. 31, 2014
Investments [Abstract]
Schedule of Held-To-Maturity Investments Estimated Fair Value of Investments
		Amortized		Gross		Estimated
		Cost		Unrealized		Fair Value
				Losses
	2014
	Certificates of deposit, commercial paper	$	10,698,982	$	2,209	$	10,696,773
	2013
	Certificates of deposit, commercial paper	$	17,297,165	$	16,493	$	17,280,672
Schedule of Maturities of Held-To-Maturity Investments
		Less than		Total
		1 Year
	2014
	Certificates of deposit, commercial paper	$	10,698,982	$	10,698,982
	2013
	Certificates of deposit, commercial paper	$	17,297,165	$	17,297,165

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Property and Equipment [Abstract]
Schedule of Property and Equipment
		December 31,
		2014			2013
	Furniture and fixtures	$	50,391		$	10,780
	Computers		24,174			13,175
	Lab equipment		447,423			39,357
	Total		521,988			63,312
	Accumulated depreciation		(76,454	)		(9,559	)
	Property and equipment, net	$	445,534		$	53,753

Accrued_Expenses_Tables

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2014
Accrued Expenses [Abstract]
Schedule of Accrued Expenses
		December 31,
		2014		2013
	Compensation and related benefits	$	519,092	$	356,588
	Patent fees		40,000		40,000
	Deferred Rent		51,155		—
	Accrued clinical trial expense		195,721		106,462
		$	805,968	$	503,050

Notes_Payable_Tables

Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2014
Notes Payable [Abstract]
Schedule of future principal payments under notes payable agreement
	Years ending December 31,
	2015	$	397,465
	2016		1,223,502
	2017		1,223,502
	2018		155,531
	Total	$	3,000,000

License_Agreements_Tables

License Agreements (Tables)	12 Months Ended
	Dec. 31, 2014
License Agreements [Abstract]
Schedule of Future Minimum Royalty Payments
	Year ended December 31,
	2015	$	33,000
	2016		33,000
	2017		283,000
	2018		33,000
	2019		33,000
	Thereafter		99,000
	Total	$	514,000

Stock_Warrants_Liability_Table

Stock Warrants Liability (Tables)	12 Months Ended
	Dec. 31, 2014
Stock Warrants Liability [Abstract]
Summary of Stock Warrants Liability Activity
		Number of			Weighted		Weighted		Weighted
		Warrants			Average		Average		Average
					Exercise		Remaining		Fair Value
					Price		Contractual
							Life (in years)
	Outstanding at December 31, 2012		20,549		$	4.83		8.9	$	1.64
	Granted		—			—		—		—
	Exercised		—			—		—		—
	Expired/cancelled		—			—		—		—
	Outstanding at December 31, 2013		20,549		$	4.83		8.2	$	5.95
	Granted		52,695		$	4.27		10	$	6.13
	Exercised		(73,244	)	$	4.43		9.5	$	6.08
	Expired/cancelled		—			—		—		—
	Outstanding at December 31, 2014		—		$	—		—	$	—

Stockholders_Equity_Deficit_Ta

Stockholders' Equity (Deficit) (Tables)	12 Months Ended
	Dec. 31, 2014
Stockholders' Equity [Abstract]
Summary of Activity of Common Stock Warrants Retroactively Adjusted for Reverse Stock Split		Common Stock
		Warrants
	Outstanding, December 31, 2012		53,159
	Granted to underwriters		125,000
	Exercised		—
	Expired		—
	Outstanding, December 31, 2013		178,159
	Granted to lenders		52,695
	Exercised		(88,462	)
	Expired		—
	Outstanding, December 31, 2014		142,392
Schedule of Components of Stock-based Compensation Included in Net Loss		For the years ended
		December 31,
		2014				2013
	Employee stock options	$	570,760			$	131,178
	Non-employee stock options		495,683				415,212
	Restricted stock awards		—				25,534
		$	1,066,443			$	571,924
Schedule of Stock Option Valuation Assumptions		December 31,
		2014				2013
	Dividend yield		0	%			0	%
	Expected volatility		107-110	%			90-112	%
	Risk-free interest rate		2.06-2.23	%			1.39-2.26	%
	Expected lives (years)		5.9-6.5				5.75-6.5
Schedule of Stock Option Activity
		Shares				Weighted
						Average
						Exercise
						Price
	Outstanding, December 31, 2012		590,047			$	0.71
	Granted		186,736			$	10.07
	Exercised		(80,706	)		$	0.67
	Forfeited		(62,595	)		$	1.96
	Outstanding, December 31, 2013		633,482			$	3.36
	Granted		507,879			$	6.3
	Exercised		(78,664	)		$	0.6
	Forfeited		(44,107	)		$	3.19
	Outstanding, December 31, 2014		1,018,590			$	5.04
Schedule of Options Outstanding, Exercisable, and Vested or Expected to Vest	Options Outstanding							Options Exercisable			Options Vested or Expected to Vest
	Balance	Weighted			Weighted			Balance	Weighted	Weighted	Balance	Weighted	Weighted
	as of	Average			Average			as of	Average	Average	as of	Average	Average
	12/31/14	Remaining			Exercise			12/31/14	Remaining	Exercise	12/31/14	Remaining	Exercise
		Contractual			Price				Contractual	Price		Contractual	Price
		Life							Life			Life
		(Years)							(Years)			(Years)
	1,018,590	7.81			$5.04			473,696	5.99	$2.67	473,696	5.99	$2.67

Income_Tax_Tables

Income Tax (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax [Abstract]
Schedule of Components of Income Tax Expense
		Years ended December 31,
		2014			2013
	Current expense:
	Federal	$	—		$	—
	State		—			—
	Deferred expense (benefit):
	Federal	$	—		$	—
	State		—			—
	Total	$	—		$	—
Schedule of Income Tax Rate Reconciliation
		Years ended December 31,
		2014			2013
	Federal income tax expense at statutory rate	$	(4,162,691	)	$	(2,247,353	)
	State and local income taxes, net of federal benefit		(344,247	)		(186,475	)
	Non-deductible expenses		239,213			4,985
	Prior-period true-up		(161,018	)		162,061
	Research & development credit		(454,031	)		(180,687	)
	Change in tax rate		—			32,774
	Stock based compensation		135,008			—
	Increase in valuation allowance		4,747,766			2,414,695
		$	—		$	—
Schedule of Deferred Tax Assets and Liabilities
		December 31,
		2014			2013
	Deferred tax assets:
	Net operating loss carryforward	$	8,141,857		$	4,167,785
	Research & development credit		961,445			424,739
	Other		484,954			247,966
	Valuation allowance		(9,588,256	)		(4,840,490	)
	Deferred income taxes	$	—		$	—

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2014
Net Loss Per Share [Abstract]
Schedule of Net Loss Per Share		For the years ended
		December 31,
		2014				2013
	Net loss	$	(12,243,211	)		$	(6,609,864	)
	Net loss: Non-controlling interest		(454,394	)			(198,516	)
	Beneficial conversion charge		—				(2,300,000	)
	Preferred Stock Dividend		—				(361,668	)
	Net loss applicable to common stockholders	$	(11,788,817	)		$	(9,073,016	)
	Weighted-average number of common shares used in net loss per share applicable to common stockholders—basic and diluted		6,454,866				3,747,357
	Net loss per share applicable to common stockholders—basic and diluted	$	(1.83	)		$	(2.42	)
Schedule of Potentially Dilutive Securities
		For the years ended
		December 31,
		2014			2013
	Outstanding stock options		1,018,590			633,482
	Common stock warrants		142,392			178,159

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]
	Years ending December 31,
	2015	$	192,833
	2016		218,271
	2017		224,282
	2018		231,010
	2019		194,401
	Total	$	1,060,797

Organization_Details

Organization (Details) (Heat Biologics I, Inc [Member])	Dec. 31, 2014	Dec. 31, 2013
Heat Biologics I, Inc [Member]
Noncontrolling Interest [Line Items]
Ownership interest in subsidiary	92.50%	92.50%

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (USD $)	12 Months Ended		1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Sep. 30, 2014	Aug. 31, 2014	Dec. 31, 2012
Property, Plant and Equipment [Line Items]
Capitalized Costs Property And Equipment	$500
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted cash	101,129	1,252
Minimum cash balance to pay trademark fees	1,000
Minimum cash balance with lending bank	100,000
Cash balance insured	250,000	250,000
Cash balance uninsured	3,704,026
Beneficial conversion charge		2,300,000
Effective conversion price, per share		$6.14
Fair value, per share		$8.81
Marketing Expense	135,372	135,366
Secured Loan - Square 1 Bank [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of common stock issuable through warrants				52,695
Exercise price of warrants				$4.27
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of common stock issuable through warrants		20,549			20,549
Debt discount	323,021
Number of shares issued from cashless exercise of warrant			17,664
Warrant [Member] | Secured Loan - Square 1 Bank [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Debt discount				$323,021
Heat Biologics I, Inc [Member]
Noncontrolling Interest [Line Items]
Ownership interest in subsidiary	92.50%	92.50%
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Lab equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Assumptions Used in Valuation of Warrants) (Details) (Stock Warrants Liability [Member])	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate		2.75%
Expected dividend yield	0.00%	0.00%
Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate	2.23%
Expected volatility	73.00%	71.60%
Expected life (years)	7 years 9 months 18 days	7 years 11 months 16 days
Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate	2.46%
Expected volatility	100.00%	71.90%
Expected life (years)	10 years	8 years 7 months 6 days

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Schedule of Change in Fair Value of the Level III Common Stock Warrant Liability ) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Summary of Significant Accounting Policies [Abstract]
Fair value, beginning balance	$122,590	$92,150
Issuance of new warrants	323,021
Change in fair value during the period	7,263	30,440
Cashless exercise during the period	-452,874
Fair value, ending balance		$122,590

Summary_of_Significant_Account6

Summary of Significant Accounting Policies (Schedule of Changes In Fair Value of Level III Stock Warrants Liability) (Details) (Fair Value, Measurements, Recurring [Member], USD $)	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock Warrant Liability	($122,590)
Total Liabilities measured at fair value	-122,590
Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock Warrant Liability
Total Liabilities measured at fair value
Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock Warrant Liability
Total Liabilities measured at fair value
Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock Warrant Liability	-122,590
Total Liabilities measured at fair value	($122,590)

Investments_Schedule_of_HeldTo

Investments (Schedule of Held-To-Maturity Investments) (Details) (Certificates of deposit, commercial paper [Member], USD $)	Dec. 31, 2014	Dec. 31, 2013
Certificates of deposit, commercial paper [Member]
Schedule of Trading Securities and Other Trading Assets [Line Items]
Amortized Cost	$10,698,982	$17,297,165
Gross Unrealized Losses	2,209	16,493
Estimated Fair Value	10,696,773	17,280,672
Less than 1 year	10,698,982	17,297,165
Total	$10,698,982	$17,297,165

Property_and_Equipment_Schedul

Property and Equipment (Schedule of Property and Equipment ) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Total	$521,988	$63,312
Accumulated depreciation	-76,454	-9,559
Property and equipment, net	445,534	53,753
Depreciation	66,895	6,348
Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	7 years
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Total	50,391	10,780
Estimated useful lives	7 years
Computers [Member]
Property, Plant and Equipment [Line Items]
Total	24,174	13,175
Estimated useful lives	5 years
Lab equipment [Member]
Property, Plant and Equipment [Line Items]
Total	$447,423	$39,357
Estimated useful lives	5 years

Accrued_Expenses_Schedule_of_A

Accrued Expenses (Schedule of Accrued Expenses) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Accrued Expenses [Abstract]
Compensation and related benefits	$519,092	$356,588
Patent fees	40,000	40,000
Deferred Rent	51,155
Accrued clinical trial expense	195,721	106,462
Total	$805,968	$503,050

Debt_Issuance_Costs_Narrative_

Debt Issuance Costs (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Aug. 31, 2014
Debt Instrument [Line Items]
Amortization of debt issuance costs	$37,556	$28,229
Warrant [Member]
Debt Instrument [Line Items]
Debt discount	323,021
Secured Loan - Square 1 Bank [Member]
Debt Instrument [Line Items]
Deferred financing cost	27,500
Debt Instrument, Term	42 months
Secured Loan - Square 1 Bank [Member] | Warrant [Member]
Debt Instrument [Line Items]
Debt discount			$323,021

Convertible_Notes_Payable_Narr

Convertible Notes Payable (Narrative) (Details) (USD $)	1 Months Ended
	Jul. 31, 2013	Oct. 31, 2011	Dec. 31, 2014	Dec. 31, 2013	Oct. 20, 2011
Debt Instrument [Line Items]
Debt instrument, carrying amount					$950,000
Interest rate					12.00%
Debt conversion description		The note is convertible into common or Series A preferred stock at the latest valuation. The type of security converted will depend on whether common or Series A preferred stock is issued as part of a successful future equity raise of at least $7.5 million at the qualified offering price.
Maturity date		31-Oct-19
Accrued interest				25,364
Payments on convertible notes payable	$197,099

Notes_Payable_Narrative_Detail

Notes Payable (Narrative) (Details) (USD $)

1 Months Ended

12 Months Ended

1 Months Ended

Oct. 31, 2011

Dec. 31, 2014

Sep. 30, 2014

Dec. 31, 2011

Aug. 31, 2012

Aug. 31, 2013

Jul. 31, 2013

Jan. 31, 2013

Oct. 20, 2011

Dec. 31, 2013

Dec. 31, 2012

Aug. 31, 2014

Dec. 14, 2013

Aug. 07, 2012

Feb. 28, 2014

Jan. 10, 2013

Debt Instrument [Line Items]

Principal loan amount

$950,000

Maturity date

31-Oct-19

Reverse stock split, conversion ratio

0.4348

Warrant [Member]

Debt Instrument [Line Items]

Number of shares of common stock issuable through warrants

20,549

20,549

Debt discount

323,021

Number of shares issued from cashless exercise of warrant

17,664

Secured Loan - Square 1 Bank [Member]

Debt Instrument [Line Items]

Term of loan

42 months

Number of shares of common stock issuable through warrants

52,695

Debt instrument, minimum interest rate

3.05%

Debt instrument, maximum interest rate

6.30%

Repayment of principal made during period

0

Interest paid during period

24,150

Exercise price of warrants

$4.27

Secured Loan - Square 1 Bank [Member] | Warrant [Member]

Debt Instrument [Line Items]

Debt discount

323,021

Secured Loan - Square 1 Bank [Member] | Common Stock [Member]

Debt Instrument [Line Items]

Number of shares issued from cashless exercise of warrant

17,664

Secured Loan - Square 1 Bank [Member] | Maximum [Member]

Debt Instrument [Line Items]

Principal loan amount

7,500,000

North Carolina Biotechnology Center Loan Agreement [Member]

Debt Instrument [Line Items]

Annual installments

5.00%

North Carolina Biotechnology Center Loan Agreement [Member] | Series A Preferred Stock [Member]

Debt Instrument [Line Items]

Warrant expiration date

13-Dec-21

Loan And Security Agreement Tranche A [Member]

Debt Instrument [Line Items]

Principal loan amount

1,000,000

Accrues interest, annual

6.00%

Accrues interest, monthly

3.00%

Term of loan

36 months

Periodic payments, frequency

Monthly

Loan And Security Agreement Term Loan B [Member]

Debt Instrument [Line Items]

Annual installments

5.00%

5.00%

Accrues interest, annual

4.25%

Repayment of note payable and bank loan

725,000

Loan And Security Agreement Term Loan B [Member] | Maximum [Member]

Debt Instrument [Line Items]

Principal loan amount

225,000

Loan And Security Agreement [Member]

Debt Instrument [Line Items]

Number Of Warrants Post Reverse Stock Split

7,609

Number of shares of common stock issuable through warrants

3,072

Loan And Security Agreement [Member] | Series A Preferred Stock [Member]

Debt Instrument [Line Items]

Preferred stock shares purchased by warrant issued

17,500

Exercise price of warrants

4.83

Warrant expiration date

7-Aug-22

Loan And Security Agreement Second Amendment [Member]

Debt Instrument [Line Items]

Outstanding loan

200,000

Collateral amount

200,000

Maturity date

9-Jan-14

Loan And Security Agreement Second Amendment [Member] | Maximum [Member]

Debt Instrument [Line Items]

Principal loan amount

200,000

Tranche 1 Loan [Member] | Secured Loan - Square 1 Bank [Member]

Debt Instrument [Line Items]

Principal loan amount

1,500,000

Debt instrument, amount outstanding

1,500,000

Tranche 2 Loan [Member] | Secured Loan - Square 1 Bank [Member]

Debt Instrument [Line Items]

Principal loan amount

1,500,000

Debt instrument, amount outstanding

1,500,000

Tranche 3 Loan [Member] | Secured Loan - Square 1 Bank [Member] | Scenario, Forecast [Member]

Debt Instrument [Line Items]

Principal loan amount

2,250,000

Tranche 4 Loan [Member] | Secured Loan - Square 1 Bank [Member] | Scenario, Forecast [Member]

Debt Instrument [Line Items]

Principal loan amount

2,250,000

Tranche 1 and 2 Loan [Member] | Secured Loan - Square 1 Bank [Member]

Debt Instrument [Line Items]

Debt instrument, amount outstanding

3,000,000

Notes_Payable_Schedule_of_Futu

Notes Payable (Schedule of Future Principal Payments Under Notes Payable Agreement) (Details) (USD $)	Dec. 31, 2014
Future principal payments
2015	$397,465
2016	1,223,502
2017	1,223,502
2018	155,531
Total	$3,000,000

License_Agreements_Narrative_D

License Agreements (Narrative) (Details) (USD $)

1 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

Jul. 31, 2011

Apr. 30, 2009

Dec. 31, 2014

Dec. 31, 2013

Jun. 30, 2009

Jul. 31, 2008

Apr. 30, 2011

Feb. 28, 2011

Sep. 23, 2014

30-May-17

Dec. 31, 2011

Sep. 08, 2010

Jun. 26, 2009

Dec. 19, 2011

Additional consideration

$12,500

Minimum royalty payment for first three years, per year

10,000

Minimum royalty payment for remainer life of agreement, per year

20,000

Milestone payment

250,000

Option fees

2,000

Exercise of stock options

10,000

37,936

54,042

Unpaid License Fees

160,000

Annual interest on outstanding balance

18.00%

University [Member]

Percentage of all issued and outstanding stock to be issued with license agreement

2.50%

5.00%

10.00%

Not for profit corporation fee one [Member]

License Costs

5,000

Not for profit corporation fee two [Member]

License Costs

50,000

License Agreement ("143") [Member]

Reimbursement of for past patent fees

50,000

License Agreement ("143") [Member] | Patent [Member]

License Costs

14,158

License Agreement ("J110") [Member]

Reimbursement of for past patent fees

10,000

License Agreement ("J110") [Member] | Patent [Member]

License Costs

1,055

License agreement ("SS114A") [Member]

Reimbursement of for past patent fees

37,381

License Agreement For Multiple Myeloma [Member]

License Costs

5,000

Maintenance fee

3,000

License Agreement For Multiple Myeloma [Member] | Maximum [Member]

Maintenance fee

30,000

Heat Biologics I, Inc [Member]

Unpaid License Fees

$102,784

Heat Biologics I, Inc [Member] | Not for profit corporation fee two [Member]

Percentage of issued and outstanding stock owned

7.50%

License_Agreements_Schedule_of

License Agreements (Schedule of Future Minimum Royalty Payments) (Details) (USD $)	Dec. 31, 2014
License Agreements [Abstract]
2015	$33,000
2016	33,000
2017	283,000
2018	33,000
2019	33,000
Thereafter	99,000
Total	$514,000

Stock_Warrants_Liability_Detai

Stock Warrants Liability (Details) (Warrant [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Warrant [Member]
Common Stock Warrants
Outstanding, beginning balance	20,549	20,549
Granted	52,695
Exercised	-73,244
Expired/cancelled
Outstanding, ending balance		20,549	20,549
Weighted Average Exercise Price
Outstanding, at the beginning of year	$4.83	$4.83
Granted	$4.27
Exercised	$4.43
Expired/cancelled
Outstanding, at the end of year		$4.83	$4.83
Weighted Average Remaining Contractual Life (in years)
Outstanding, beginning balance	0 years	8 years 2 months 12 days	8 years 10 months 24 days
Granted	10 years
Exercised	9 years 6 months
Outstanding, at the end of year	0 years	8 years 2 months 12 days	8 years 10 months 24 days
Weighted Average Fair Value
Outstanding, at the beginning of year	$5.95	$1.64
Granted	$6.13
Exercised	$6.08
Expired/cancelled
Outstanding, at the end of year		$5.95	$1.64
Aggregate Intrinsic Value
Aggregate intrinsic value of preferred stock warrants	$0	$46,646

Stockholders_Equity_Deficit_Na

Stockholders' Equity (Deficit) (Narrative) (Details) (USD $)	1 Months Ended			12 Months Ended		1 Months Ended
	Sep. 30, 2013	Aug. 31, 2013	Jul. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2013
Stockholders' Equity [Abstract]
Common stock, par value per share				$0.00	$0.00
Common stock, shares authorized				50,000,000	50,000,000
Common stock, shares issued				6,492,622	6,375,426
Common stock, shares outstanding				6,492,622	6,375,426
Shares issued for initial public offering	100,000	100,000	2,500,000
Price per share	$10	$10	$10
Proceeds from initial public offering	$1,000,000	$1,000,000	$25,000,000	$27,000,000
Proceeds from initial public offering, net	930,000	930,000	22,400,000	24,300,000
Common stock issued for conversion of preferred stock				1,696,683
Shares issued as stock dividend				36,167
Preferred stock dividend					361,668
Class of Stock [Line Items]
Minimum net proceeds from public offering for automatic conversion				15,000,000
Reverse stock split, conversion ratio				0.4348
Shares issuable upon conversion of preferred stock				0.4348
Series 1 Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, liquidation preference				$4.83
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, par value per share				$0.00	$0.00
Preferred stock, shares authorized				2,000,000	2,000,000
Preferred stock, shares issued					0
Preferred stock, shares outstanding				0	0
Price per share				$2.10
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, par value per share					$0.00
Preferred stock, shares authorized					4,100,000
Series B-1 Preferred Stock [Member]
Class of Stock [Line Items]
Price per share				$2.67
Preferred stock, dividend rate				5.00%
Preferred stock, dividend amount per share				$6.14
Preferred stock, liquidation preference				$6.14
Proceeds from issuance of private placement						$5,000,000
Issuance of preferred stock, shares						1,891,419
Series B-2 Preferred Stock [Member]
Class of Stock [Line Items]
Price per share				$5
Preferred stock, dividend rate				5.00%
Preferred stock, dividend amount per share				$11.50
Preferred stock, liquidation preference				$11.50

Stockholders_Equity_Deficit_Co

Stockholders' Equity (Deficit) (Common Stock Warrants) (Details) (USD $)	1 Months Ended	2 Months Ended	9 Months Ended	12 Months Ended			1 Months Ended
	Feb. 28, 2014	Feb. 28, 2014	Aug. 31, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2011	Sep. 30, 2014	Aug. 31, 2014
Secured Debt [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of common stock issuable through warrants								52,695
Exercise price of warrant liabilities								$4.27
Common Stock Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of common stock issuable through warrants	15,218	15,218	20,549
Exercise price of warrant liabilities			$4.83	$11.03
Expiration term			10 years		5 years	10 years
Exercise price						$0.48
Price per share					$12.50
Common Stock Warrants
Outstanding, beginning balance		178,159		178,159	53,159
Granted				52,695	125,000	32,610
Exercised				-88,462
Expired
Outstanding, ending balance				142,392	178,159
Number of shares issued from cashless exercise of warrant	14,318	8,065
Common Stock Warrants [Member] | Secured Debt [Member]
Common Stock Warrants
Number of shares issued from cashless exercise of warrant							17,664

Stockholders_Equity_Deficit_Eq

Stockholders' Equity (Deficit) (Equity Compensation Plan) (Narrative) (Details) (USD $)	12 Months Ended		1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Jun. 30, 2014	Dec. 31, 2012	Apr. 30, 2011	Dec. 31, 2009
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding stock options	1,018,590	633,482		590,047
Granted	507,879	186,736
Forfeited	44,107	62,595
Stock-based compensation expense	$1,066,443	$571,924
Weighted average grant-date fair value	$5.66	$8.51
Fair value of stock options vested	1,704,121
Unrecognized stock-based compensation expense	$3,872,221
unrecognized stock-based compensation expense, recognition period	14 months 27 days
2014 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Incentive Plan, shares authorized	500,000		500,000
Expiration term			10 years
Outstanding stock options	436,748
2009 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Incentive Plan, shares authorized	869,565				652,174	217,391
Expiration term	10 years
Outstanding stock options	581,842	633,482
2009 and 2014 Plans [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding stock options	1,018,590
Granted	1,416,091
Forfeited	115,398
Common shares available for grant	68,872

Stockholders_Equity_Deficit_Sc

Stockholders' Equity (Deficit) (Schedule of Stock-based Compensation) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation	$1,066,443	$571,924
Outstanding stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation	570,760	131,178
Non-employee stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation	495,683	415,212
Restricted stock awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation		$25,534

Stockholders_Equity_Deficit_Sc1

Stockholders' Equity (Deficit) (Schedule of Stock Option Valuation Assumptions) (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	107.00%	90.00%
Risk-free interest rate	2.06%	1.39%
Expected lives (years)	5 years 10 months 24 days	5 years 9 months
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	110.00%	112.00%
Risk-free interest rate	2.23%	2.26%
Expected lives (years)	6 years 6 months	6 years 6 months

Stockholders_Equity_Deficit_Sc2

Stockholders' Equity (Deficit) (Schedule of Stock Option Activity) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Shares
Outstanding, beginning balance	633,482	590,047
Granted	507,879	186,736
Exercised	-78,664	-80,706
Forfeited	-44,107	-62,595
Outstanding, ending balance	1,018,590	633,482
Weighted Average Exercise Price
Outstanding, beginning balance	$3.36	$0.71
Granted	$6.30	$10.07
Exercised	$0.60	$0.67
Forfeited	$3.19	$1.96
Outstanding, ending balance	$5.04	$3.36

Stockholders_Equity_Deficit_Su

Stockholders' Equity (Deficit) (Summary of Outstandng Stock Options) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Options Outstanding
Balance	1,018,590
Weighted average remaining contractual life	7 years 9 months 22 days
Weighted Average Exercise Price	$5.04
Options Exercisable
Balance	473,696
Weighted average remaining contractual life	5 years 11 months 26 days
Weighted average exercise price	$2.67
Options Vested or Expected to Vest
Balance	473,696
Weighted average remaining contractual life	5 years 11 months 26 days
Weighted average exercise price	$2.67

Income_Tax_Schedule_of_Income_

Income Tax (Schedule of Income Tax Expense (Benefit)) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Current expense:
Federal
State
Deferred expense (benefit):
Federal
State
Total

Income_Tax_Schedule_of_Income_1

Income Tax (Schedule of Income Tax Rate Differences) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax [Abstract]
Federal income tax expense at statutory rate	($4,162,691)	($2,247,353)
State and local income taxes, net of federal benefit	-344,247	-186,475
Non-deductible expenses	239,213	4,985
Prior-period true-up	-161,018	162,061
Research & development credit	-454,031	-180,687
Change in tax rate		32,774
Stock based compensation	135,008
Increase in valuation allowance	4,747,766	2,414,695
Total

Income_Tax_Schedule_of_Deferre

Income Tax (Schedule of Deferred Tax Assets) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Deferred tax assets:
Net operating loss carryforward	$8,141,857	$4,167,785
Research & development credit	961,445	424,739
Other	484,954	247,966
Valuation allowance	-9,588,256	-4,840,490
Deferred income taxes

Income_Tax_Narrative_Details

Income Tax (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Income Tax [Abstract]
Statutory federal tax rate	34.00%
Change in valuation allowance	$4,747,766
Operating Loss Carryforwards [Line Items]
U.S. net operating loss carryforwards	$42,039,675
Minimum [Member]
Operating Loss Carryforwards [Line Items]
U.S. net operating loss carryforwards expiration dates	31-Dec-23

Related_Party_Narrative_Detail

Related Party (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Related Party Transaction [Line Items]
Related party payable balance	$26,750	$13,000
Related party receivable balance	48,642	24,946
Management [Member]
Related Party Transaction [Line Items]
Consulting fees	28,000	34,480
Board [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Officers' Compensation	32,000	5,000
Board [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Officers' Compensation	$37,000	$10,870

Net_Loss_Per_Share_Reverse_Sto

Net Loss Per Share (Reverse Stock Split) (Details)	1 Months Ended	12 Months Ended
	31-May-13	Dec. 31, 2014
Net Loss Per Share [Abstract]
Reverse stock split, conversion ratio		0.4348
Reverse stock split	0.4348

Net_Loss_Per_Share_Schedule_of

Net Loss Per Share (Schedule of Reconciliation of Net Loss Applicable to Common Shareholders) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Net Loss Per Share [Abstract]
Net Loss	($12,243,211)	($6,609,864)
Net loss - non-controlling interest	-454,394	-198,516
Beneficial conversion charge		-2,300,000
Preferred stock dividend		-361,668
Net loss attributable to common stockholders	($11,788,817)	($9,073,016)
Weighted average number of common shares used in net loss attributable to common stockholders - basic and diluted	6,454,866	3,747,357
Net loss per share attributable to common stockholders-basic and diluted	($1.83)	($2.42)

Net_Loss_Per_Share_Schedule_of1

Net Loss Per Share (Schedule of Antidilutive Securities) (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Outstanding stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	1,018,590	633,482
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	142,392	178,159

Commitments_and_Contingencies_1

Commitments and Contingencies (Narrative) (Details) (USD $)	0 Months Ended	1 Months Ended	12 Months Ended
	Jan. 24, 2014	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Commitments and Contingencies [Abstract]
Lease term	5 years
Monthly lease rent	$10,341	$11,638		$4,046
Rent expense			$100,973	$48,377

Commitments_and_Contingencies_2

Commitments and Contingencies (Future Minimum Payments for Operating Lease Obligations) (Details) (USD $)	Dec. 31, 2014
Approximate future minimum payments for its operating lease obligations that have initial remaining non-cancellable terms in excess of one year
2015	$192,833
2016	218,271
2017	224,282
2018	231,010
2019	194,401
Total	$1,060,797

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	12 Months Ended		0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Mar. 15, 2015	Mar. 09, 2015	Mar. 10, 2015
Subsequent Event [Line Items]
Net proceeds from the Offering, after deducting underwriting discounts and commissions and other estimated offering expenses		$540
Subsequent Event [Member] | Severance agreement with Matthew Czajkowski [Member] | Vesting prior to the date of resignation [Member]
Subsequent Event [Line Items]
Exercise period			10 years
Subsequent Event [Member] | Severance agreement with Matthew Czajkowski [Member] | Vesting after the date of resignation [Member]
Subsequent Event [Line Items]
Exercise period			90 days
Subsequent Event [Member] | Consulting agreement with Danforth Advisors, LLC [Member]
Subsequent Event [Line Items]
Written notice period required to terminate agreement by the Company				30 days
Subsequent Event [Member] | Underwriting Agreement with Aegis Capital Corp. [Member]
Subsequent Event [Line Items]
Shares of common stock issued					1,640,000
Offering price (in dollars per share)					$6.50
Net proceeds from the Offering, after deducting underwriting discounts and commissions and other estimated offering expenses					$11,100,000
Subsequent Event [Member] | Underwriting Agreement with Aegis Capital Corp. [Member] | Over-allotments [Member]
Subsequent Event [Line Items]
Shares of common stock issued					246,000